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ABSTRACT 
 
Campylobacter is a major cause of bacterial gastroenteritis in humans and is commonly 
transmitted via undercooked poultry meat, unpasteurized milk and contaminated water. Over the 
years, Campylobacter has developed resistance to clinically important antibiotics including 
fluoroquinolones. Because of its significance in public health, both the Centers for Disease 
Control and Prevention and the World Health Organization has listed antibiotic resistant 
Campylobacter as a serious threat. Fluoroquinolone resistant mutants in Campylobacter occurs 
spontaneously and the resistance is mediated by the synergistic effect of the CmeABC multi-
drug efflux pump and point mutations in the gyrA gene. Thus, antisense inhibition of cmeABC 
expression is a promising approach to combat fluoroquinolone resistance in Campylobacter. 
Previous studies have shown the specific inhibition of cmeABC expression by an antisense 
peptide nucleic acid (PNA) targeting the translational start of CmeA, but whether the PNA can 
be used as an adjuvant to potentiate fluoroquinolone antibiotics remains to be determined. 
Toward this end, in vitro and in vivo experiments were conducted to examine the efficacy of the 
PNA in reducing the emergence of spontaneous fluoroquinolone resistant mutants during 
treatment with a fluoroquinolone antibiotic. When fluoroquinolone-susceptible Campylobacter 
was treated with ciprofloxacin in culture media, resistant mutants emerged quickly and 
eventually replaced the susceptible population. However, addition of the PNA to the 
ciprofloxacin treatment prevented the emergence of resistant mutants completely, indicating the 
potentiating effect of the PNA on ciprofloxacin. Based on the in vitro results, the efficacy of the 
PNA was further evaluated in vivo using a Campylobacter infected chicken model. When given 
by oral gavage, the PNA was able to reduce, but unable to completely eliminate the emergence 
x 
of fluoroquinolone resistant mutants in Campylobacter in the intestinal tract of chickens treated 
with enrofloxacin. These results demonstrate the potentiating effect of the PNA on 
fluoroquinolone antibiotics and warrant additional studies to further optimize the anti-CmeABC 
approach as an adjunct therapy for antibiotic treatment of campylobacteriosis.   
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CHAPTER 1.    GENERAL INTRODUCTION 
 
Introduction  
Campylobacter is a leading cause of gastroenteritis in humans. It is commonly present in 
the food production environments and is transmitted to humans via unpasteurized milk, 
contaminated water, and undercooked poultry meat. Campylobacter jejuni and Campylobacter 
coli are the most prevalent species causing campylobacteriosis. Clinical symptoms usually 
constitute acute watery or bloody diarrhea, nausea, fever, headache, and severe abdominal 
cramps. Although the infection is usually enteric and mild, there are cases of Campylobacter-
induced severe complications, such as Guillain-Barré syndrome (GBS), Miller Fisher syndrome 
(MFS), reactive arthritis, bacteremia, meningitis, Urinary Tract Infections (UTIs) and 
cardiovascular complications. 
Fortuitously, most Campylobacter infections are generally self-limiting and usually 
resolves itself within a few days. However, in cases where the patient is immunocompromised, 
elderly, young or pregnant, antibiotic treatment may be necessary. Some clinically severe cases 
with prolonged illness may also require antibiotic therapy, in these cases, fluoroquinolones and 
macrolides are the drugs of choice for therapeutic treatment. Unfortunately reports of antibiotic 
resistance in Campylobacter have been increasing drastically over the past decade. 
Fluoroquinolone resistance for instance has been on the rise all around the world. Prior to 1992, 
fluoroquinolone resistance in Campylobacter was very rare, however, recent reports from USA 
and other countries show a remarkable prevalence of fluoroquinolone resistant Campylobacter. 
Campylobacter has also been known to easily and rapidly develop resistance to fluoroquinolone 
antibiotics over the course of the treatment in patients with gastroenteritis. Because of the 
importance of Campylobacter as a zoonotic pathogen and its rising resistance to clinically 
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important antibiotics, both WHO and CDC have listed antibiotic-resistant Campylobacter as a 
serious threat to public health. 
As a zoonotic pathogen, Campylobacter is exposed to antibiotics used for animal 
production and human medicine. When exposed to fluoroquinolone antibiotics, Campylobacter 
readily develops spontaneous resistant mutants that survive the treatment and eventually replace 
the fluoroquinolone susceptible Campylobacter under selection pressure. Fluoroquinolone 
antibiotics inhibit DNA gyrase in Campylobacter and resistance to this class of antibiotics is due 
to spontaneous point mutations in the gyrA gene. However, gyrA mutations alone are not 
sufficient and the function of the CmeABC efflux pump is also required for conferring clinically 
relevant resistance. The synergistic effect of the CmeABC efflux pump and point mutations in 
the gyrA gene lead to high levels of fluoroquinolone resistance. As the major efflux system in 
Campylobacter, CmeABC extrudes structurally diverse antibiotics including fluoroquinolones. 
Thus, inhibition of CmeABC represents a promising strategy for combating antibiotic-resistant 
Campylobacter. 
To address the challenge with fluoroquinolone resistance in Campylobacter, various 
efforts have been made to target the CmeABC efflux pump. One of the strategies is to inhibit the 
expression of this efflux system by use of antisense peptide nucleic acid (PNA). PNA is a 
synthetic polymer that mimics nucleic acids, the ability to base pair with DNA and RNA allows 
PNA to perform antisense inhibition in a highly specific manner. Indeed, previous work has 
demonstrated that a PNA (CmeA1) targeting the translational start region of cmeA specifically 
inhibited expression of the cmeABC operon in Campylobacter. However, whether the CmeA1 
PNA is able to reduce the emergence of fluoroquinolone resistant mutants in Campylobacter has 
not been examined. To close this knowledge gap and facilitate the development of an adjunct 
3 
 
therapy for fluoroquinolone antibiotics, we conducted both in vitro and in vivo experiments to 
evaluate the efficacy of the PNA in potentiating fluoroquinolone antibiotics.  
In the first set of experiments, the efficacy of the CmeA1 PNA was examined in culture 
media. Treatment of C. jejuni with ciprofloxacin and the CmeA1 PNA completely prevented the 
emergence of fluoroquinolone resistant mutants, whereas treatment with ciprofloxacin alone 
generated resistant mutants which continued to multiply during the treatment and replaced the 
susceptible population at the end. The CmeA1 PNA alone did not affect the development of 
fluoroquinolone resistance. A scrambled sequence PNA (control) was also tested, the co-
treatment with control PNA was unable to prevent the emergence of fluoroquinolone resistant 
mutants. These findings demonstrate that CmeA1 PNA is able to potentiate the killing effect of 
ciprofloxacin and prevented the emergence of fluoroquinolone resistant mutants in culture 
media. 
In the second set of experiments using Campylobacter-infected chicken as a model 
system, we demonstrated that the CmeA1 PNA was able to initially reduce the emergence of 
fluoroquinolone resistant mutants in birds treated with enrofloxacin. However, the PNA was not 
able to completely eliminate the emergence of resistant mutants in the chicken intestinal tract. 
The results indicate the potential use of the CmeA1 PNA as an adjunct therapy for 
fluoroquinolone antibiotics, but additional studies are needed to optimize the treatment schemes. 
 
Dissertation Organization 
This dissertation is organized into five chapters, including a general introduction, a 
literature review, 2 chapters on experimental data, and a final summary. Chapter 1 is a general 
introduction for the Ph.D. project. Chapter 2 is a literature review of antibiotic resistance in 
Campylobacter, the function of the CmeABC efflux pump, and the potential of PNA in 
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inhibiting expression of CmeABC. Chapter 3 encompasses the in vitro experiments conducted to 
evaluate the efficacy of the PNA in culture media. Chapter 4 includes experiments assessing the 
in vivo efficacy of PNA using chickens as an animal model. Chapter 5 is the summary of this 
project which includes the general conclusions and future directions.  
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CHAPTER 2.    LITERATURE REVIEW 
 
Campylobacter  
Campylobacter is a gram negative, curved rod bacterium. Most of the species are motile 
and have a single polar unsheathed flagellum at one or both ends. They are usually between 0.5 
to 5 microns in length and 0.2 to 0.9 microns in width. They are microaerophilic and grow best 
in an atmosphere containing 5% - 10% oxygen (1). Campylobacter is best grown at 42 °C as 
they are thermophilic and do not multiply at temperatures below 30°C (2, 3). Some species, such 
as Campylobacter jejuni, can hydrolyze hippurate, while others, such as Campylobacter coli, are 
unable to.  This phenotypic difference was often used to differentiate between C. jejuni and C. 
coli (4). However, currently PCR or MALDI-TOF MS techniques are routinely used to identify 
Campylobacter species (5, 6). More recently, whole genome sequence analysis of 
Campylobacter isolates has become routine, which provides high-resolution genomic data for 
molecular typing and phylogenic analysis of isolates from different sources (7, 8).  
As an enteric organism, Campylobacter causes gastroenteritis in humans, and C. jejuni 
and C. coli are the two species commonly associated with the disease. The infectious dose of C. 
jejuni for humans is estimated to be between 500–800 organisms (9). In 1981 a British medical 
doctor, Robinson, was able to show this by swallowing 500 organisms in pasteurized milk. His 
results satisfied Koch’s Postulates, proving the low infectious dose of C. jejuni (10).  
The incubation period after ingestion of C. jejuni is 24-72 hours; however, in some cases 
it has been seen to last a week or longer (11). The most common clinical manifestation of 
infection is diarrhea, which can be quite severe. This is often accompanied by fever, abdominal 
pain and nausea. These symptoms are clinically indistinguishable from those caused by other 
enteric pathogens like Salmonella and Shigella and therefore diagnosis is made by isolating the 
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pathogen from stool samples (12). The disease is usually self-limiting and symptoms are 
resolved in a week; however, sometimes patients, particularly immunocompromised patients, 
have relapsing illness that lasts several weeks (13). Complications arising from C. jejuni 
infections can be quite severe, and heavy gastrointestinal hemorrhaging can occur. Pancreatitis 
and cholecystitis have also been reported in patients with severe complications from C. jejuni 
infection (14). Extraintestinal complications can also occur. For example, C..jejuni infection has 
been associated with Guillain–Barré syndrome (GBS) (1, 15-19),  Miller Fisher syndrome (20), 
reactive arthritis (21, 22), bacteremia, septicemia, meningitis, Bell's palsy, Urinary Tract 
Infections (UTIs), and cardiovascular complications (15, 23, 24).  
In cases when due to severity or because the patient is immunocompromised clinical 
treatment is needed, fluoroquinolones and macrolides are the first choices for antibiotic treatment 
of campylobacteriosis (25). However, Campylobacter is becoming increasingly resistant to 
clinically important antibiotics (26-34), compromising their effectiveness in clinical therapy. 
Campylobacter has been known to easily develop resistance to fluoroquinolone antibiotics over 
the course of the treatment, sometimes as rapidly as after 1 day of treatment in patients (35-37), 
rendering the treatment ineffective.  
Fluoroquinolone resistant Campylobacter was very rare in the United States before 1992, 
however. this has changed over the years with reports of increasing prevalence of 
fluoroquinolone resistance amongst Campylobacter isolated from USA and Canada (38-40). 
Prevalence of fluoroquinolone resistant Campylobacter have been increasing in European 
countries as well (41-46). In some reports of Asia and Africa, fluoroquinolone resistance rates 
have reached  as high as 100% (33, 47, 48). Although there is a trend of increased macrolide 
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resistance in Campylobacter, the prevalence rates are generally lower than fluoroquinolone 
resistance (49-51).  
With C. jejuni, fluoroquinolone-resistant mutants develop rapidly during treatment and 
the resistant population continues to persist even after removal of the antibiotic selection 
pressure, which suggests that no fitness cost is associated with the mutation leading to resistance 
(51-53). In contrast, macrolide-resistant mutants develop slowly, and the process involves a 
multistep development and requires prolonged exposure to the antibiotic (50). It has been 
observed that once the selection pressure is removed, the majority of the population reverts to 
macrolide-susceptible Campylobacter as macrolide-resistant mutants cannot compete with 
macrolide-susceptible Campylobacter, suggesting that there is a fitness cost associated with the 
resistance-conferring mutation (50, 51). The difference between fluroquinolone and macrolide in 
resistance development and fitness impact may explain why fluoroquinolone-resistant 
Campylobacter is much higher than macrolide-resistant Campylobacter worldwide.  
 
Epidemiology, Etiology and Complications of Campylobacteriosis 
Campylobacter is the leading cause of bacterial foodborne diarrheal disease worldwide. 
Symptoms can range from mild to serious including acute watery or bloody diarrhea, nausea, 
fever, headache, and abdominal pain with severe cramps (12, 24). Campylobacter has been 
identified as a common precursor to Guillain-Barré syndrome (GBS), an acute neuropathy (17, 
18). The complication occurs post infection, when antibodies produced against the pathogen’s 
surface structures cross-react with antigens on nerve endings. This autoimmune pathology leads 
to neuron damage that causes acute flaccid paralysis (54). GBS is the most common form of 
acute flaccid paralysis in the post-polio era (55). Miller Fisher syndrome (MFS), a variant of 
GBS, is also seen to be commonly associated with Campylobacter infections (56). Theses 
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neuropathies are a result of mimicry of the lipopolysaccharides (LPS) of C. jejuni to the 
gangliosides in peripheral neurons, leading to host antibodies attacking and damaging its own 
nerve cells (57). Acute reactive arthritis may also develop post Campylobacter infections (22). It 
is a spondyloarthropathy that usually develops within 4 weeks of the infection and is 
characterized by acute joint inflammation (58). The symptoms are generally joint and 
musculoskeletal related, but cardiac complications have also been observed (59, 60).  
Campylobacteriosis is more common in children, the elderly and immunocompromised 
individuals (61). According to the Centers for Disease Control, there are about 1.3 million cases 
of Campylobacter infection each year in the United States, incurring medical cost between $1.3 
to 6.8 billion dollars yearly (23, 62, 63). The incident reports of campylobacteriosis have also 
increased in Europe. Based on the Community Zoonoses Reports of the European Food Safety 
Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC), 
Campylobacter has been the most commonly reported zoonotic pathogen in the EU, surpassing 
Salmonella and Yersinia (64, 65).  
Although epidemiological data from Africa, Asia, and the Middle East are still limited 
and incomplete, a few studies conducted indicate that Campylobacter infection is endemic in 
these regions (33, 47). Due to population-level immunity in endemic regions, infection in 
developing countries is usually limited to children. It has been suggested that exposure in early 
life leads to the development of protective immunity (66-68). C. jejuni and C. coli are the most 
common species associated with Campylobacter enteritis in humans (69). A study conducted in 
hospitals of Yangzhou, China showed that 4.84% of 3,061 patients with diarrhea were PCR 
positive for C. jejuni, with the highest prevalence being detected in children younger than 7 years 
old (70). In another study conducted in Beijing, China, 14.9% (142/950) of patients with 
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gastroenteritis were reported to be positive for Campylobacter species (127 with C. jejuni and 15 
with C. coli) (71). A report from Kolkata, India showed 7.0% (222/3186) of hospitalized patients 
with gastroenteritis were positive for Campylobacter, out of which 70% of the isolates were 
identified as C. jejuni (72). With the estimate that Campylobacter causes 400 to 500 million 
cases of diarrhea each year globally, it is undeniable that Campylobacter has a significant impact 
on global health (9). In fact, it was included as a pathogen of high concern in a report published 
by the World Health Organization in 2017 (73). 
The intestinal tracts of food production animals are a reservoir for Campylobacter and the 
main source of infection for human campylobacteriosis is consumption of improperly prepared 
and contaminated animal foods such as poultry and raw milk (74-79). In the Netherlands cecal 
contents collected directly from chicken farms showed that 97% of the samples from layer farms 
and 93% samples from broiler farms were positive for Campylobacter (80). Screening of chicken 
meat from retail outlets in France displayed a high prevalence of Campylobacter (76% products 
positive) with the majority being C. jejuni. In Australia, Campylobacter spp. were detected in 
retail chicken meat (90%), lamb (38%), pork (31%) (81). Similarly in the US Campylobacter 
was detected in 76% of organic chicken products and 74% in conventional chicken products 
(82). Clearly, Campylobacter is highly prevalent in food production animals and are exposed to 
antibiotics that are routinely used on animal farms for growth promotion, disease prevention and 
control. 
Studies show that conventional poultry farms have a higher percentage of antimicrobial 
resistant Campylobacter than organic farms where antimicrobials are not used (83). 
Campylobacter is a zoonotic pathogen and is therefore exposed to antibiotics used in both animal 
production and human medicine. This has raised concerns about using antibiotics important in 
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human medicine on animal farms as it may select antibiotic resistant Campylobacter that is 
transmitted to humans via the food chain. In 2005, the Food and Drug Administration banned the 
use of fluoroquinolones on poultry farms in the United States (32, 84). European countries have 
also implemented bans on usage of subtherapeutic doses of antibiotics as a feed additive to 
promote growth in food production animals.  
Despite these measures, antimicrobial resistance in Campylobacter continues to persist 
and antibiotic-resistant Campylobacter is still on the rise (51, 85, 86). Patients infected with 
fluoroquinolone resistant Campylobacter tend to have a prolonged duration of diarrhea when 
compared to patients infected with fluoroquinolone susceptible Campylobacter (87). 
Fluoroquinolone resistance has been increasing rapidly in the US and Canada (29), even though 
it was rare before 1992 (51). Similarly, European countries have also seen the rise of 
fluoroquinolone resistant Campylobacter, with Spain reporting 72% Campylobacter was 
fluoroquinolone resistant (88), Greece reporting 55% (45), Finland reporting 46% (44), and 
Germany reporting 30% (42). In Thailand, over 80% Campylobacter isolates are resistant to 
fluoroquinolones (51, 88). Unlike the drastically elevated prevalence of fluoroquinolone 
resistance, macrolide resistance in Campylobacter is still relatively low (10% or lower in the 
US); however, it is on the rise in Asia and Africa (51, 89). In Korea, macrolide resistance was 
reported to be present in 14 - 50% of the Campylobacter isolates (90, 91), and 17% was reported 
from Thailand (92), Tetracycline resistance amongst Campylobacter isolates are high all around 
the world (93-95). 
 
Antibiotic Resistance Mechanisms in Campylobacter 
Campylobacter displays intrinsic resistance to novobiocin, bacitracin, vancomycin, β-
lactams, and polymyxins due to the absence of antibiotic targets and/or the low affinity of these 
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antibiotic to target sites (96). Thus, these antibiotics are rarely used for clinical treatment of 
campylobacteriosis. Although fluoroquinolones, macrolides, tetracyclines, and aminoglycosides 
are effective against Campylobacter, acquired resistance to these antibiotics is increasingly 
reported. Campylobacter can confer resistance to these antibiotics through multiple mechanisms. 
Blocking antibiotics from reaching their target is a simple mechanism used by 
Campylobacter for resistance. By altering membrane permeability Campylobacter can restrict 
the entry of antibiotics into the cells. For example, modulating the expression of porA, encoding 
the major outer membrane porin (MOMP), can affect the permeability of the membrane, which 
prevents the uptake of certain antibiotics such as macrolides and most β-lactams (96). Another 
example of restricting entry of antibiotics into the cell is through the production of 
lipooligosaccharide that confers resistance to hydrophobic drugs. The outer membrane and 
surface polysaccharides are essential components that determine the permeability of the cell, and 
knocking out the lipooligosaccharide (LOS) made Campylobacter more susceptible to antibiotics 
(97). 
Enzymatic deactivation of antibiotics is also a mechanism employed by Campylobacter 
for antibiotic resistance. Chloramphenicol inhibits bacterial protein synthesis by preventing the 
elongation step when it binds to the 50S rRNA. This can be countered by the cat gene that 
encodes an acetyltransferase, which modifies chloramphenicol to prevent it from binding to 
ribosomes (98). This plasmid borne chloramphenicol resistance gene has been reported in 
Campylobacter (99). β-lactam antibiotics are also susceptible to enzymatic degradation from β-
lactamases. These enzymes are encoded by a variety of different genes that are easily acquired 
by Campylobacter. Some common genes identified in Campylobacter include OXA-type β-
lactamases and metallo-β-lactamases (100). 
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Target protection is a well-established mechanism for antibiotic resistance present in 
many pathogenic bacteria. Tetracyclines bind to ribosomes and interfere with the elongation step 
during peptide synthesis by inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex 
(101). Tetracycline resistance in Campylobacter is conferred by the tetO gene that encodes the 
Tet(O) protein, which protects against tetracycline binding to ribosomal A site. Tet(O) is a 
member of a class of proteins called ribosomal protection proteins or RPPs. Other members of 
this class of proteins include Tet(M), Tet(S), Tet(T) and Tet(Q) (102). Evidence shows that 
Tet(O)  is acquired by Campylobacter through horizontal transfer (103).  
Target modification is another important mechanism in Campylobacter and is responsible 
for resistance to 2 classes of important antibiotics. Campylobacter easily acquires mutations in 
the 23S rRNA leading to erythromycin resistance. The A2075G mutation in the 23S rRNA has 
been identified as a prevalent mutation contributing to high-level erythromycin resistance in 
Campylobacter (104, 105). Point mutations in the quinolone resistance-determining region 
(QRDR) of the gyrA gene is responsible for ciprofloxacin resistance in C. jejuni and C. coli 
(106). DNA gyrase is essential for bacterial growth (107). Fluoroquinolone antibiotics such as 
ciprofloxacin bind to DNA gyrase while it is attached to the DNA to form a stable complex that 
traps the enzyme in place, this complex inhibits progression of bacterial DNA synthesis leading 
to bacterial death(108). DNA gyrase has two subunits encoded by the genes gyrA and gyrB and 
certain point mutations in gyrA lead to Campylobacter resistance to fluoroquinolones. 
Additionally, these mutations do not seem to alter the function of DNA gyrase, which means 
there isn’t a fitness cost associated with the acquisition of the resistance (51, 53, 109). This 
phenomenon could explain why fluoroquinolone resistance has persisted on poultry farms 
despite the withdrawal of the antibiotics in 2005. As mentioned below many studies showed that 
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fluoroquinolone resistant Campylobacter is still prevalent on poultry farms in the united states 
even after the fluoroquinolone ban (85). Since the acquisition of the resistance does not reduce 
the fitness of Campylobacter, fluoroquinolone-resistant Campylobacter is expected to continue 
to persist even in the absence of antibiotic selection pressure (28, 109, 110). 
Another major mechanism for antimicrobial resistance in Campylobacter is reduced 
intracellular accumulation of antibiotics via efflux, such as the multidrug efflux pump CmeABC 
that confers resistance to fluoroquinolones, macrolides, tetracyclines, florfenicols, and β-lactams 
as well as other toxic compounds (28, 111). Since it gives rise of a multidrug resistance 
phenotype, this mechanism is extremely concerning as it severely restricts the options for anti-
microbial therapy. Furthermore, CmeABC work in synergy with the other mechanisms 
mentioned above to further elevate the resistance levels (34, 87, 96, 105, 112). The synergistic 
effect between efflux and the acquisition of resistance genes and mutations further compromise 
the effectiveness of therapeutic strategies. For these reasons, the CmeABC efflux pump and its 
potential inhibition are discussed in more details below. 
 
Multidrug Efflux Pumps in Campylobacter 
Multidrug efflux pumps enable Campylobacter to actively resist antibiotics and constitute 
a vital mechanism of antibiotic resistance (111-114). Multidrug transporters can be differentiated 
based on their energy sources. ATP-binding cassette (ABC) transporters use ATP as an energy 
source, while secondary transporters use a transmembrane electrochemical gradient of protons or 
sodium ions to facilitate transport (115). Secondary multidrug transporters are further 
categorized into four superfamilies based on their structural properties. These include the 
resistance–nodulation–division (RND) family consisting of three proteins located in three 
different cellular compartments (inner membrane, periplasm and outer membrane), the major 
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facilitator superfamily (MFS) that consists of 12–14 transmembrane domains, the multidrug and 
toxic compound extrusion (MATE) family which also has 12 transmembrane domains but with 
significant sequence differences from MFS transporters, and the small multidrug resistance 
(SMR) family comprising of small proteins usually containing 4 TMs (115, 116). 
Two multidrug efflux pumps, CmeABC and CmeDEF, have been characterized in 
Campylobacter, both belonging to the RND family of transporters. CmeABC is the major efflux 
pump in C. jejuni and contributes to resistance to a variety of antimicrobials. Unlike CmeABC, 
CmeDEF has only a moderate effect on antimicrobial resistance. CmeDEF interacts with 
CmeABC in maintaining cell viability (113). Sequencing of the genomic DNA of C. jejuni 
NCTC 11168 revealed 14 putative drug efflux transporters of different families, but most of 
these transporters remain unknown in terms of function (116). Most of these transporters, 
however, do not show a synergistic effect with other resistance mechanisms like CmeABC does 
(114). 
The CmeABC multidrug efflux pump is an energy dependent RND type efflux pump. It 
has three subunits CmeA, CmeB and CmeC. The CmeA subunit is a periplasmic fusion protein, 
CmeB is the efflux transporter present in the inner membrane, and CmeC is the outer membrane 
protein (111, 117). These three subunits form a channel in the membrane of the bacteria to 
extrude antimicrobials and toxic compounds or metabolites. Therefore, CmeABC is not just 
responsible for broad spectrum resistance to antimicrobial agents in Campylobacter, it is also 
necessary for Campylobacter colonization in the intestinal tract of animals as it also expels bile 
salts (118, 119). The efflux pump is encoded by a three gene operon, cmeA, cmeB and cmeC, 
with only one promoter in front of cmeA. The peptide sequence of CmeB shows 41% similarity 
to AcrB (111), which is a major efflux pump in Escherichia coli (120). Furthermore, cmeABC is 
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subject to regulation by CmeR, a 210-amino-acid protein encoded by cmeR upstream of cmeA. 
Studies showed that CmeR is a transcriptional regulator of the TetR family, binds to the 
promoter of cmeABC, and represses expression of this efflux system (121, 122). 
Bile salts also have a significant impact on the expression levels of cmeABC. Evidence 
shows that transcription of cmeABC is upregulated in the presence of Bile salts, so is the 
production of the CmeABC proteins (119). This increase is due to the fact that bile salts inhibit 
the binding of CmeR to the promoter of cmeABC, liberating the operon from repression (119). 
Increase in expression levels of the CmeABC Efflux pump in the presence of bile salts modestly 
increases antimicrobial resistance levels in Campylobacter (119, 123, 124). 
Another transcriptional regulator for the CmeABC Efflux pump is CosR. CosR is an 
essential response regulator in C. jejuni and regulates many genes involved in cellular functions 
such as lipid metabolism, protein synthesis, and energy production, etc (125). Initially 
transcriptomic analysis showed an increase in transcription levels of cmeA, cmeB and cmeC 
when CosR was knocked down. Further experiments demonstrated that CosR directly binds to 
the cmeABC promoter, and the binding site is 17bp upstream to the CmeR binding site (125). 
This finding indicates that expression of cmeABC is dynamically regulated by multiple factors. 
As expression of this large efflux pump can be costly for Campylobacter, constitutive expression 
is only at a modest level, but enhanced expression of cmeABC occurs in the presence of toxic 
compounds (such as bile and antibiotics), facilitating the adaptation of Campylobacter to 
environmental changes (121-123). 
CmeABC functions synergistically with other mechanisms in conferring clinically 
relevant antibiotic resistance. For example, the efflux pump is necessary for acquiring and 
maintaining fluoroquinolone resistance and for the emergence of fluoroquinolone resistant 
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mutants in C. jejuni because gyrA mutations alone are not sufficient for resistance to the 
antibiotics (114, 124, 126). Similarly, CmeABC efflux pump works in synergy with target 
mutations in the ribosomal proteins to confer resistance to macrolides in Campylobacter (127). 
The importance of CmeABC efflux pump in mediating antibiotic resistance has been clearly 
shown, providing a strong rationale for inhibition to reduce the emergence of antibiotic-resistant 
Campylobacter. 
 
Inhibition of the CmeABC Efflux Pump 
Owing to their key role in antibiotic resistance, inhibition of multidrug efflux transporters 
represents a promising strategy to combat antimicrobial resistance. Unsurprisingly, many studies 
have been performed to identify small molecule inhibitors to interfere with the activity of efflux 
pumps with the intention of improving the usefulness of antibacterial agents already in use (128-
135). These Efflux Pump Inhibitors or EPIs are being extensively researched for broad-spectrum 
inhibition of efflux pumps, particularly in gram negative bacteria. While the strategy of 
inhibiting efflux pumps to re-sensitize the resistant bacteria to clinically available antibiotics is a 
good one, these EPIs tend to be toxic at the concentrations needed for inhibition and have 
therefore not been put into use (128). Furthermore, EPIs do not always produce consistent 
inhibition against different efflux pumps and are therefore not as broad-spectrum as initially 
believed (132-134, 136). Many studies were conducted to reduce or eliminate the toxic effects of 
EPIs, but were met with limited success: either the structural changes reduce the inhibition 
potency of the EPIs or it is unable to negate the toxic side effects (137-140). 
Different from EPIs that block the function of efflux pumps, another strategy is to inhibit 
the expression of efflux transporters. A novel synthetic molecule called peptide nucleic acid or 
PNA has been successfully used to knock down expression of the CmeABC efflux pump and re-
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sensitize antibiotic-resistant Campylobacter to clinically relevant antibiotics like 
fluoroquinolones and macrolides that are used to treat Campylobacter infections (141, 142). 
 
Peptide Nucleic Acids 
PNA was first created in the laboratory of organic chemist Prof. Ole Buchardt and 
biochemist Peter Nielsen during the 1980s (143). It is a synthetic polymer with a backbone 
composed of N‐(2‐aminoethyl) glycine units instead of a sugar-phosphate backbone naturally 
present in nucleic acids (144). It has the nucleobases attached to the glycine nitrogen via 
carbonyl methylene linkers and can base pair with DNA and RNA using the Watson Crick 
hydrogen bonding scheme (143-146). PNA oligomers bind with high sequence discrimination or 
specificity to complementary oligomers. Due to the N‐(2‐aminoethyl) glycine backbone, PNA 
molecules are neutral, unlike negatively charged DNA and RNA, therefore they are able to form 
stable duplexes and triplexes with DNA and RNA with greater affinity since they lack 
electrostatic repulsion.  
PNA is also resistant to enzymatic degradation and therefore very stable within a cell 
(147). However, entry into cells is a challenge and they must be conjugated to a delivery 
mechanism. HPLC analysis of PNA in human serum and cellular extracts confirms stability of 
PNA in the presence of proteolytic enzymes (148). PNA injected intravenously in rats was 
detected in all major organs, such as kidney, liver, and spleen, and was recovered from the urine 
24 hours after it was administered (149). This data demonstrates that PNA is extremely stable in 
diverse conditions. 
PNA molecules have been used for various applications as a tool in molecular biology 
and biotechnology. Due to the high specificity, PNA can discriminate between single base pair 
mismatches, and this high sequence discrimination is an invaluable tool in molecular biology 
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(150-152). They have also been used for development of biosensors and for diagnostics 
purposes. For example, PNA was designed to target microRNAs (miRs) that are aberrantly 
expressed in prostate cancer. These microRNA levels can be detected in biofluids, making them 
an ideal noninvasive biomarker for diagnosis (153). Fluorescent in situ hybridization (FISH) can 
also be performed using PNA probes (154). PNA is able to distinguish point mutations with high 
specificity (155). This characteristic was exploited to detect clarithromycin resistance in 
Helicobacter pylori suspensions (156). It is a rapid way to detect resistance without having to use 
fastidious culturing methods. 
PNA has great potential in helping us combat multidrug resistant Campylobacter as it can 
serve as a targeted antisense therapeutic (157, 158). As mentioned earlier however, PNA cannot 
easily gain entry into cells, and to facilitate their uptake, they must first be linked to cell 
penetrating peptides or CPPs. Many cell-penetrating peptides have been documented over the 
years. They are fairly short (< 30 amino acids) and can translocate various cargos into cells (159, 
160). A PNA molecule targeting a specific gene for antisense inhibition conjugated to an 
appropriate CPP can be potentially used as an antisense therapeutic.  
PNA has been successfully used to inhibit bacterial growth in Escherichia coli by 
targeting functional sites of rRNA. The effect is similar to antibiotics that inhibit translation like 
tetracycline. Control PNAs, i.e. PNAs with unrelated or mismatched sequences show no 
inhibitory effect (161). In an effort to develop PNA as a broad spectrum therapeutic, a study was 
conducted to inhibit growth in all gram-negative bacteria by targeting the rpoD gene. The anti-
rpoD PNAs displayed bactericidal effect against multidrug-resistant Escherichia coli, Salmonella 
enterica, Klebsiella pneumoniae, and Shigella flexneri in vitro and in vivo. This study was also 
able to demonstrate that treatment with PNA of infected human gastric mucosal epithelial cells 
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exhibited the complete inhibition of bacterial growth and had no influence on morphology and 
growth of human mucosal cells (162).  
PNAs have been used to inhibit a multi-drug resistant K. pneumoniae strain. In this case, 
PNA was designed against 2 essential genes gyrA and ompA. The PNAs alone did not permeate 
the bacteria, however, when conjugated to the (KFF)3K cell penetrating peptide, they were able 
to inhibit the growth of the MDR K. pneumoniae at concentrations of 20 µM and 40 µM, 
respectively. The bactericidal effects were seen within 6 hours. This experiment was also 
conducted in MDR K. pneumoniae infected human cell lines, the CPP-PNAs were able to cure 
the infection with no noticeable toxicity to the human cells (163). A very similar study was 
conducted in MDR Acinetobacter baumannii, where PNA was designed to target carA, an 
essential Acinetobacter gene. In vitro testing was conducted with four clinical strains of MDR A. 
baumannii and their PNA construct was able to inhibit bacterial growth at a concentration of 
1.25 µM. In vivo testing was conducted in the Galleria mellonella model of sepsis. Two doses (5 
µM and 20 µM) of the CPP-PNA targeting the essential gene (carA) were evaluated. The results 
demonstrated that the low dose of PNA did not have any effect but the high dose of the CPP-
PNA was able to significantly reduce the mortality rate of the caterpillars (164). The use of PNA 
and other antisense oligonucleotides as bactericidal agents is being researched as an alternative 
for the antibiotics currently being used (165). 
Broad spectrum PNAs, however, kill pathogenic and non-pathogenic bacteria 
indiscriminately and it is also likely that targeting an essential gene will lead to the development 
and selection of resistant mutants as it has happened with antibiotics. Targeting resistance 
mechanisms with PNA to revert the bacteria to be susceptible is thus becoming a popular 
strategy. Colleen M. Courtney and Anushree Chatterjee were able to re-sensitize drug-resistant 
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Escherichia coli to β-lactam antibiotics by using targeted antisense translational inhibition of the 
TEM-1 β-lactamase transcript with PNA (166). 
In Campylobacter, PNA targeting the CmeABC efflux pump has been used successfully 
to knock down the expression of this multidrug efflux system. The optimal PNA was identified 
by selecting the best sequence for antisense inhibition of the translational initiation site of cmeA 
(141, 142, 167). The cmeA-specific PNA significantly reduced the expression level of CmeABC 
as seen by Western blotting analysis and decreased the minimum inhibitory concentration (MIC) 
of antibiotics. Although PNA has shown the potential to inhibit CmeABC and consequently 
sensitize Campylobacter to antibiotics, it requires further development before it can used as 
therapeutic adjuvant. Unlike EPIs, PNA does not seem to have significant toxic effect, as in vivo 
studies conducted in a mouse model demonstrated no toxic effect (143). 
 
Conclusions and Future Directions 
Campylobacter is a significant burden to public health with fewer treatment options as it 
has developed resistance to clinically important antibiotics. As a highly adaptable bacterial 
organism, Campylobacter possesses multiple mechanisms for antibiotic resistance. Of particular 
note is the multidrug efflux transporter CmeABC, which confers broad resistance to antibiotics 
and toxic compounds. By targeting the multidrug resistance system of Campylobacter, it is 
possible to potentiate the effectiveness of currently available antibiotics while minimizing the 
rapid emergence of fluoroquinolone resistant mutants often seen in patients receiving treatment 
for Campylobacteriosis. Toward this direction, PNA has shown a great potential to specifically 
inhibit the expression of the cmeABC efflux pump and work as an adjunct therapeutic. However, 
the previous work was done in culture media, and further studies are needed to determine the 
efficacy of PNA in inhibiting the expression of CmeABC under various conditions and the 
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emergence of antibiotic resistant mutants during antibiotic treatment. Additionally, its potency 
needs to be evaluated in vivo to determine whether it is effective in inhibiting CmeABC of 
Campylobacter in the intestinal tract, where the environment is much more complex that in 
culture media. 
 
References 
1. Epps SV, Harvey RB, Hume ME, Phillips TD, Anderson RC, Nisbet DJ. 2013. 
Foodborne Campylobacter: infections, metabolism, pathogenesis and reservoirs. Int J 
Environ Res Public Health 10:6292-304. 
2. Levin RE. 2007. Campylobacter jejuni: A Review of its Characteristics, Pathogenicity, 
Ecology, Distribution, Subspecies Characterization and Molecular Methods of Detection. 
Food Biotechnology 21:271-347. 
3. Hazeleger WC, Janse JD, Koenraad PM, Beumer RR, Rombouts FM, Abee T. 1995. 
Temperature-dependent membrane fatty acid and cell physiology changes in coccoid 
forms of Campylobacter jejuni. Applied and Environmental Microbiology 61:2713-2719. 
4. Hébert GA, Hollis DG, Weaver RE, Lambert MA, Blaser MJ, Moss CW. 1982. 30 years 
of campylobacters: biochemical characteristics and a biotyping proposal for 
Campylobacter jejuni. Journal of Clinical Microbiology 15:1065-1073. 
5. Wang G, Clark CG, Taylor TM, Pucknell C, Barton C, Price L, Woodward DL, Rodgers 
FG. 2002. Colony Multiplex PCR Assay for Identification and Differentiation of 
Campylobacter jejuni, C. coli, C. lari, C. upsaliensis, and C. fetus subsp. fetus. Journal of 
Clinical Microbiology 40:4744-4747. 
6. Alispahic M, Hummel K, Jandreski-Cvetkovic D, Nöbauer K, Razzazi-Fazeli E, Hess M, 
Hess C. 2010. Species-specific identification and differentiation of Arcobacter, 
Helicobacter and Campylobacter by full-spectral matrix-associated laser 
desorption/ionization time of flight mass spectrometry analysis. Journal of Medical 
Microbiology 59:295-301. 
7. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, Chillingworth T, 
Davies RM, Feltwell T, Holroyd S, Jagels K, Karlyshev AV, Moule S, Pallen MJ, Penn 
CW, Quail MA, Rajandream MA, Rutherford KM, van Vliet AH, Whitehead S, Barrell 
BG. 2000. The genome sequence of the food-borne pathogen Campylobacter jejuni 
reveals hypervariable sequences. Nature 403:665-8. 
8. Gundogdu O, Bentley SD, Holden MT, Parkhill J, Dorrell N, Wren BW. 2007. Re-
annotation and re-analysis of the Campylobacter jejuni NCTC11168 genome sequence. 
BMC Genomics 8:162. 
22 
 
9. Ruiz-Palacios GM. 2007. The health burden of Campylobacter infection and the impact 
of antimicrobial resistance: playing chicken, p 701-3, Clin Infect Dis, vol 44, United 
States. 
10. Robinson DA. 1981. Infective dose of Campylobacter jejuni in milk. Br Med J (Clin Res 
Ed) 282:1584. 
11. Blaser MJ. 1997. Epidemiologic and Clinical Features of Campylobacter jejuni 
Infections. The Journal of Infectious Diseases 176:S103-S105. 
12. Ban Mishu A, Blaser MJ. 1995. Campylobacter jejuni and the Expanding Spectrum of 
Related Infections. Clinical Infectious Diseases 20:1092-1099. 
13. Kapperud G, Lassen J, Ostroff SM, Aasen S. 1992. Clinical features of sporadic 
Campylobacter infections in Norway. Scand J Infect Dis 24:741-9. 
14. Pitkänen T, Pönkä A, Pettersson T, Kosunen TU. 1983. Campylobacter Enteritis in 188 
Hospitalized Patients. JAMA Internal Medicine 143:215-219. 
15. Nachamkin I. 2002. Chronic effects of Campylobacter infection. Microbes and Infection 
4:399-403. 
16. Van Vliet AHM, Ketley JM. 2001. Pathogenesis of enteric Campylobacter infection. 
Journal of Applied Microbiology 90:45S-56S. 
17. Allos BM. 1997. Association between Campylobacter infection and Guillain-Barre 
syndrome. J Infect Dis 176 Suppl 2:S125-8. 
18. Poropatich KO, Walker CL, Black RE. 2010. Quantifying the association between 
Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health 
Popul Nutr 28:545-52. 
19. Wierzba TF, Abdel-Messih IA, Gharib B, Baqar S, Hendaui A, Khalil I, Omar TA, 
Khayat HE, Putnam SD, Sanders JW, Ng LK, Price LJ, Scott DA, Frenck RR. 2008. 
Campylobacter infection as a trigger for Guillain-Barre syndrome in Egypt. PLoS One 
3:e3674. 
20. Prendergast MM, Moran AP. 2000. Lipopolysaccharides in the development of the 
Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory 
peripheral neuropathies. J Endotoxin Res 6:341-59. 
21. Berden JH, Muytjens HL, van de Putte LB. 1979. Reactive arthritis associated with 
Campylobacter jejuni enteritis. Br Med J 1:380-1. 
22. Hannu T, Mattila L, Rautelin H, Pelkonen P, Lahdenne P, Siitonen A, Leirisalo‐Repo M. 
2002. Campylobacter‐triggered reactive arthritis: a population‐based study. 
Rheumatology 41:312-318. 
23. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. 2015. Global 
Epidemiology of Campylobacter Infection. Clin Microbiol Rev 28:687-720. 
24. Man SM. 2011. The clinical importance of emerging Campylobacter species. Nat Rev 
Gastroenterol Hepatol 8:669-85. 
23 
 
25. Wiström J, Norrby SR. 1995. Fluoroquinolones and bacterial enteritis, when and for 
whom? Journal of Antimicrobial Chemotherapy 36:23-39. 
26. Chen X, Naren G-W, Wu C-M, Wang Y, Dai L, Xia L-N, Luo P-J, Zhang Q, Shen J-Z. 
2010. Prevalence and antimicrobial resistance of Campylobacter isolates in broilers from 
China. Veterinary Microbiology 144:133-139. 
27. Xia J, Pang J, Tang Y, Wu Z, Dai L, Singh K, Xu C, Ruddell B, Kreuder A, Xia L, Ma X, 
Brooks KS, Ocal MM, Sahin O, Plummer PJ, Griffith RW, Zhang Q, Shen Z, Wang Y, 
Shen J, Fang L. 2019. High prevalence of fluoroquinolone-resistant Campylobacter in 
sheep and increased Campylobacter counts in the bile and gallbladder of sheep medicated 
with tetracycline in feed. Appl Environ Microbiol 6:87-98. 
28. Tang Y, Fang L, Xu C, Zhang Q. 2017. Antibiotic resistance trends and mechanisms in 
the foodborne pathogen, Campylobacter. Animal Health Research Reviews 18:87-98. 
29. Tang Y, Sahin O, Pavlovic N, LeJeune J, Carlson J, Wu Z, Dai L, Zhang Q. 2017. Rising 
fluoroquinolone resistance in Campylobacter isolated from feedlot cattle in the United 
States, p 494, Sci Rep, vol 7, England. 
30. Sahin O, Plummer PJ, Jordan DM, Sulaj K, Pereira S, Robbe-Austerman S, Wang L, 
Yaeger MJ, Hoffman LJ, Zhang Q. 2008. Emergence of a Tetracycline-Resistant 
Campylobacter jejuni Clone Associated with Outbreaks of Ovine Abortion in the United 
States. Journal of Clinical Microbiology 46:1663-1671. 
31. Luangtongkum T, Morishita TY, Martin L, Choi I, Sahin O, Zhang Q. 2008. Prevalence 
of Tetracycline-Resistant Campylobacter in Organic Broilers During a Production Cycle. 
Avian Diseases 52:487-490. 
32. Acheson D, Allos BM. 2001. Campylobacter jejuni Infections: Update on Emerging 
Issues and Trends. Clinical Infectious Diseases 32:1201-1206. 
33. Putnam SD, Frenck RW, Riddle MS, El-Gendy A, Taha NN, Pittner BT, Abu-Elyazeed 
R, Wierzba TF, Rao MR, Savarino SJ, Clemens JD. 2003. Antimicrobial susceptibility 
trends in Campylobacter jejuni and Campylobacter coli isolated from a rural Egyptian 
pediatric population with diarrhea. Diagnostic Microbiology and Infectious Disease 
47:601-608. 
34. García-Fernández A, Dionisi AM, Arena S, Iglesias-Torrens Y, Carattoli A, Luzzi I. 
2018. Human Campylobacteriosis in Italy: Emergence of Multi-Drug Resistance to 
Ciprofloxacin, Tetracycline, and Erythromycin. Front Microbiol 9:1906. 
35. Adler-Mosca H, Lüthy-Hottenstein J, Martinetti Lucchini G, Burnens A, Altwegg M. 
1991. Development of resistance to quinolones in five patients with campylobacteriosis 
treated with norfloxacin or ciprofloxacin. European Journal of Clinical Microbiology and 
Infectious Diseases 10:953-957. 
36. Wretlind B, Strömberg A, Östlund L, Sjögren E, Kaijser B. 1992. Rapid Emergence of 
Quinolone Resistance in Campylobacter jejuni in Patients Treated with Norfloxacin. 
Scandinavian Journal of Infectious Diseases 24:685-686. 
24 
 
37. Sjögren E, Lindblom GB, Kaijser B. 1997. Norfloxacin resistance in Campylobacter 
jejuni and Campylobacter coli isolates from Swedish patients. Journal of Antimicrobial 
Chemotherapy 40:257-261. 
38. Gupta A, Nelson JM, Barrett TJ, Tauxe RV, Rossiter SP, Friedman CR, Joyce KW, 
Smith KE, Jones TF, Hawkins MA, Shiferaw B, Beebe JL, Vugia DJ, Rabatsky-Ehr T, 
Benson JA, Root TP, Angulo FJ. 2004. Antimicrobial resistance among Campylobacter 
strains, United States, 1997-2001. Emerg Infect Dis 10:1102-9. 
39. Nachamkin I, Ung H, Li M. 2002. Increasing fluoroquinolone resistance in 
Campylobacter jejuni, Pennsylvania, USA,1982-2001. Emerg Infect Dis 8:1501-3. 
40. Gaudreau C, Gilbert H. 2003. Antimicrobial resistance of Campylobacter jejuni subsp. 
jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Antimicrob 
Agents Chemother 47:2027-9. 
41. Gallay A, Prouzet-Mauleon V, Kempf I, Lehours P, Labadi L, Camou C, Denis M, de 
Valk H, Desenclos JC, Megraud F. 2007. Campylobacter antimicrobial drug resistance 
among humans, broiler chickens, and pigs, France. Emerg Infect Dis 13:259-66. 
42. Luber P, Wagner J, Hahn H, Bartelt E. 2003. Antimicrobial resistance in Campylobacter 
jejuni and Campylobacter coli strains isolated in 1991 and 2001-2002 from poultry and 
humans in Berlin, Germany. Antimicrob Agents Chemother 47:3825-30. 
43. Pezzotti G, Serafin A, Luzzi I, Mioni R, Milan M, Perin R. 2003. Occurrence and 
resistance to antibiotics of Campylobacter jejuni and Campylobacter coli in animals and 
meat in northeastern Italy. Int J Food Microbiol 82:281-7. 
44. Hakanen AJ, Lehtopolku M, Siitonen A, Huovinen P, Kotilainen P. 2003. Multidrug 
resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-
2000. J Antimicrob Chemother 52:1035-9. 
45. Papavasileiou E, Voyatzi A, Papavasileiou K, Makri A, Andrianopoulou I, 
Chatzipanagiotou S. 2007. Antimicrobial susceptibilities of Campylobacter jejuni isolates 
from hospitalized children in Athens, Greece, collected during 2004-2005. Eur J 
Epidemiol 22:77-8. 
46. Lucey B, Cryan B, O'Halloran F, Wall PG, Buckley T, Fanning S. 2002. Trends in 
antimicrobial susceptibility among isolates of Campylobacter species in Ireland and the 
emergence of resistance to ciprofloxacin. Vet Rec 151:317-20. 
47. Isenbarger DW, Hoge CW, Srijan A, Pitarangsi C, Vithayasai N, Bodhidatta L, Hickey 
KW, Cam PD. 2002. Comparative antibiotic resistance of diarrheal pathogens from 
Vietnam and Thailand, 1996-1999. Emerg Infect Dis 8:175-80. 
48. Tjaniadi P, Lesmana M, Subekti D, Machpud N, Komalarini S, Santoso W, Simanjuntak 
CH, Punjabi N, Campbell JR, Alexander WK, Beecham HJ, 3rd, Corwin AL, Oyofo BA. 
2003. Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in 
Indonesia. Am J Trop Med Hyg 68:666-70. 
49. Gibreel A, Taylor DE. 2006. Macrolide resistance in Campylobacter jejuni and 
Campylobacter coli. J Antimicrob Chemother 58:243-55. 
25 
 
50. Luangtongkum T, Shen Z, Seng VW, Sahin O, Jeon B, Liu P, Zhang Q. 2012. Impaired 
Fitness and Transmission of Macrolide-Resistant Campylobacter jejuni in Its Natural 
Host. Antimicrobial Agents and Chemotherapy 56:1300-1308. 
51. Luangtongkum T, Jeon B, Han J, Plummer P, Logue CM, Zhang Q. 2009. Antibiotic 
resistance in Campylobacter: emergence, transmission and persistence. Future Microbiol 
4:189-200. 
52. Luo N, Pereira S, Sahin O, Lin J, Huang S, Michel L, Zhang Q. 2005. Enhanced in vivo 
fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic 
selection pressure. Proc Natl Acad Sci U S A 102:541-6. 
53. Zhang Q, Sahin O, McDermott PF, Payot S. 2006. Fitness of antimicrobial-resistant 
Campylobacter and Salmonella. Microbes and Infection 8:1972-1978. 
54. Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. 2007. Guillain-
Barré Syndrome and Preceding Infection with Campylobacter, Influenza and Epstein-
Barr Virus in the General Practice Research Database. PLOS ONE 2:e344. 
55. Ho TW, McKhann GM, Griffin JW. 1998. Human Autoimmune Neuropathies. Annual 
Review of Neuroscience 21:187-226. 
56. Godschalk PCR, Kuijf ML, Li J, St. Michael F, Ang CW, Jacobs BC, Karwaski M-F, 
Brochu D, Moterassed A, Endtz HP, van Belkum A, Gilbert M. 2007. Structural 
Characterization of Campylobacter jejuni Lipooligosaccharide Outer Cores Associated 
with Guillain-Barré and Miller Fisher Syndromes. Infection and Immunity 75:1245-1254. 
57. Ang CW, De Klerk MA, Endtz HP, Jacobs BC, Laman JD, van der Meché FGA, van 
Doorn PA. 2001. Guillain-Barré Syndrome- and Miller Fisher Syndrome-Associated 
Campylobacter jejuni Lipopolysaccharides Induce Anti-GM1 and Anti-GQ1b Antibodies 
in Rabbits. Infection and Immunity 69:2462-2469. 
58. Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM. 2007. Campylobacter 
Reactive Arthritis: A Systematic Review. Seminars in Arthritis and Rheumatism 37:48-
55. 
59. Pönkä A, Pitkänen T, Pettersson T, Aittoniemi S, Kosunen TU. 1980. Carditis and 
Arthritis Associated with Campylobacter Jejuni Infection. Acta Medica Scandinavica 
208:495-496. 
60. Hannu T, Mattila L, Rautelin H, Siitonen A, Leirisalo-Repo M. 2005. Three cases of 
cardiac complications associated with Campylobacter jejuni infection and review of the 
literature. European Journal of Clinical Microbiology and Infectious Diseases 24:619-
622. 
61. Silva J, Leite D, Fernandes M, Mena C, Gibbs P, Teixeira P. 2011. Campylobacter spp. 
as a Foodborne Pathogen: A Review. Frontiers in Microbiology 2. 
62. Fischer GH, Paterek E. 2019. Campylobacter, StatPearls. StatPearls Publishing LLC., 
Treasure Island (FL). 
26 
 
63. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, 
Griffin PM. 2011. Foodborne illness acquired in the United States--major pathogens. 
Emerg Infect Dis 17:7-15. 
64. Authority EFS. 2007. The Community Summary Report on Trends and Sources of 
Zoonoses, Zoonotic Agents, Antimicrobial resistance and Foodborne outbreaks in the 
European Union in 2006. EFSA Journal 5:130r. 
65. Anonymous. 2010. The Community Summary Report on trends and sources of zoonoses, 
zoonotic agents and food-borne outbreaks in the European Union in 2008. EFSA Journal 
8:1496. 
66. Rao MR, Naficy AB, Savarino SJ, Abu-Elyazeed R, Wierzba TF, Peruski LF, Abdel-
Messih I, Frenck R, Clemens JD. 2001. Pathogenicity and Convalescent Excretion of 
Campylobacter in Rural Egyptian Children. American Journal of Epidemiology 154:166-
173. 
67. Larrosa-Haro A, Macias-Rosales R, Sanchez-Ramirez CA, Cortes-Lopez MC, Aguilar-
Benavides S. 2010. Seasonal variation of enteropathogens in infants and preschoolers 
with acute diarrhea in western Mexico. J Pediatr Gastroenterol Nutr 51:534-6. 
68. Benoit SR, Lopez B, Arvelo W, Henao O, Parsons MB, Reyes L, Moir JC, Lindblade K. 
2014. Burden of laboratory-confirmed Campylobacter infections in Guatemala 2008-
2012: results from a facility-based surveillance system. J Epidemiol Glob Health 4:51-9. 
69. Gillespie IA, O'Brien SJ, Frost JA, Adak GK, Horby P, Swan AV, Painter MJ, Neal KR. 
2002. A case-case comparison of Campylobacter coli and Campylobacter jejuni 
infection: a tool for generating hypotheses. Emerg Infect Dis 8:937-42. 
70. Huang JL, Xu HY, Bao GY, Zhou XH, Ji DJ, Zhang G, Liu PH, Jiang F, Pan ZM, Liu 
XF, Jiao XA. 2009. Epidemiological surveillance of Campylobacter jejuni in chicken, 
dairy cattle and diarrhoea patients. Epidemiol Infect 137:1111-20. 
71. Chen J, Sun XT, Zeng Z, Yu YY. 2011. Campylobacter enteritis in adult patients with 
acute diarrhea from 2005 to 2009 in Beijing, China. Chin Med J (Engl) 124:1508-12. 
72. Mukherjee P, Ramamurthy T, Bhattacharya MK, Rajendran K, Mukhopadhyay AK. 
2013. Campylobacter jejuni in hospitalized patients with diarrhea, Kolkata, India. Emerg 
Infect Dis 19:1155-6. 
73. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, 
Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, 
Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. 
2018. Discovery, research, and development of new antibiotics: the WHO priority list of 
antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318-327. 
74. Robinson DA, Jones DM. 1981. Milk-borne campylobacter infection. British Medical 
Journal (Clinical research ed) 282:1374-1376. 
75. Porter IA, Reid TMS. 1980. A milk-borne outbreak of Campylobacter infection. Journal 
of Hygiene 84:415-419. 
27 
 
76. Corry JEL, Atabay HI. 2001. Poultry as a source of Campylobacter and related 
organisms. Journal of Applied Microbiology 90:96S-114S. 
77. KRAMER JM, FROST JA, BOLTON FJ, WAREING DRA. 2000. Campylobacter 
Contamination of Raw Meat and Poultry at Retail Sale: Identification of Multiple Types 
and Comparison with Isolates from Human Infection. Journal of Food Protection 
63:1654-1659. 
78. Sahin O, Morishita TY, Zhang Q. 2002. Campylobacter colonization in poultry: sources 
of infection and modes of transmission. Animal Health Research Reviews 3:95-105. 
79. Sahin O, Kassem II, Shen Z, Lin J, Rajashekara G, Zhang Q. 2015. Campylobacter in 
Poultry: Ecology and Potential Interventions. Avian Diseases 59:185-200. 
80. Schets FM, Jacobs-Reitsma WF, van der Plaats RQJ, Heer LK-D, van Hoek AHAM, 
Hamidjaja RA, de Roda Husman AM, Blaak H. 2017. Prevalence and types of 
Campylobacter on poultry farms and in their direct environment. Journal of Water and 
Health 15:849-862. 
81. Walker LJ, Wallace RL, Smith JJ, Graham T, Saputra T, Symes S, Stylianopoulos A, 
Polkinghorne BG, Kirk MD, Glass K. 2019. Prevalence of Campylobacter coli and jejuni 
in retail chicken, beef, lamb and pork products in 5 three Australian states. Journal of 
Food Protection. 
82. Cui S, Ge B, Zheng J, Meng J. 2005. Prevalence and Antimicrobial Resistance of 
Campylobacter spp. and Salmonella Serovars in Organic Chickens from Maryland Retail 
Stores. Applied and Environmental Microbiology 71:4108-4111. 
83. Luangtongkum T, Morishita TY, Ison AJ, Huang S, McDermott PF, Zhang Q. 2006. 
Effect of Conventional and Organic Production Practices on the Prevalence and 
Antimicrobial Resistance of Campylobacter spp. in Poultry. Applied and Environmental 
Microbiology 72:3600-3607. 
84. Nelson JM, Chiller TM, Powers JH, Angulo FJ. 2007. Fluoroquinolone-Resistant 
Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: A 
Public Health Success Story. Clinical Infectious Diseases 44:977-980. 
85. Price LB, Lackey LG, Vailes R, Silbergeld E. 2007. The Persistence of Fluoroquinolone-
Resistant Campylobacter in Poultry Production. Environmental Health Perspectives 
115:1035-1039. 
86. Nannapaneni R, Hanning I, Wiggins KC, Story RP, Ricke SC, Johnson MG. 2009. 
Ciprofloxacin-resistant Campylobacter persists in raw retail chicken after the 
fluoroquinolone ban. Food Additives & Contaminants: Part A 26:1348-1353. 
87. Nelson JM, Smith KE, Vugia DJ, Rabatsky-Ehr T, Segler SD, Kassenborg HD, Zansky 
SM, Joyce K, Marano N, Hoekstra RM, Angulo FJ. 2004. Prolonged Diarrhea Due to 
Ciprofloxacin-Resistant Campylobacter Infection. The Journal of Infectious Diseases 
190:1150-1157. 
88. Alfredson DA, Korolik V. 2007. Antibiotic resistance and resistance mechanisms in 
Campylobacter jejuni and Campylobacter coli. FEMS Microbiology Letters 277:123-132. 
28 
 
89. Samie A, Ramalivhana J, Igumbor EO, Obi CL. 2007. Prevalence, haemolytic and 
haemagglutination activities and antibiotic susceptibility profiles of Campylobacter spp. 
isolated from human diarrhoeal stools in Vhembe District, South Africa. J Health Popul 
Nutr 25:406-13. 
90. Hong J, Kim JM, Jung WK, Kim SH, Bae W, Koo HC, Gil J, Kim M, Ser J, Park YH. 
2007. Prevalence and antibiotic resistance of Campylobacter spp. isolated from chicken 
meat, pork, and beef in Korea, from 2001 to 2006. J Food Prot 70:860-6. 
91. Shin E, Lee Y. 2007. Antimicrobial resistance of 114 porcine isolates of Campylobacter 
coli. Int J Food Microbiol 118:223-7. 
92. Serichantalergs O, Jensen LB, Pitarangsi C, Mason CJ, Dalsgaard A. 2007. A possible 
mechanism of macrolide resistance among multiple resistant Campylobacter jejuni and 
Campylobacter coli isolated from Thai children during 1991-2000. Southeast Asian J 
Trop Med Public Health 38:501-6. 
93. Karikari AB, Obiri-Danso K, Frimpong EH, Krogfelt KA. 2017. Antibiotic Resistance of 
Campylobacter Recovered from Faeces and Carcasses of Healthy Livestock. BioMed 
Research International 2017:9. 
94. Premarathne JMKJK, Anuar AS, Thung TY, Satharasinghe DA, Jambari NN, Abdul-
Mutalib N-A, Huat JTY, Basri DF, Rukayadi Y, Nakaguchi Y, Nishibuchi M, Radu S. 
2017. Prevalence and Antibiotic Resistance against Tetracycline in Campylobacter jejuni 
and C. coli in Cattle and Beef Meat from Selangor, Malaysia. Frontiers in Microbiology 
8. 
95. Moore JE, Barton MD, Blair IS, Corcoran D, Dooley JS, Fanning S, Kempf I, Lastovica 
AJ, Lowery CJ, Matsuda M, McDowell DA, McMahon A, Millar BC, Rao JR, Rooney 
PJ, Seal BS, Snelling WJ, Tolba O. 2006. The epidemiology of antibiotic resistance in 
Campylobacter. Microbes Infect 8:1955-66. 
96. Iovine NM. 2013. Resistance mechanisms in Campylobacter jejuni. Virulence 4:230-40. 
97. Oh E, Jeon B. 2015. Contribution of surface polysaccharides to the resistance of 
Campylobacter jejuni to antimicrobial phenolic compounds. The Journal of Antibiotics 
68:591-593. 
98. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. 2004. Molecular basis of bacterial 
resistance to chloramphenicol and florfenicol. FEMS Microbiology Reviews 28:519-542. 
99. Wang Y, Taylor DE. 1990. Chloramphenicol resistance in Campylobacter coli: 
nucleotide sequence, expression, and cloning vector construction. Gene 94:23-28. 
100. Griggs DJ, Peake L, Johnson MM, Ghori S, Mott A, Piddock LJV. 2009. β-Lactamase-
Mediated β-Lactam Resistance in Campylobacter Species: Prevalence of Cj0299 
(blaOXA-61) and Evidence for a Novel β-Lactamase in C. jejuni. Antimicrobial Agents 
and Chemotherapy 53:3357-3364. 
101. Chukwudi CU. 2016. rRNA Binding Sites and the Molecular Mechanism of Action of the 
Tetracyclines. Antimicrob Agents Chemother 60:4433-41. 
29 
 
102. Connell SR, Tracz DM, Nierhaus KH, Taylor DE. 2003. Ribosomal Protection Proteins 
and Their Mechanism of Tetracycline Resistance. Antimicrobial Agents and 
Chemotherapy 47:3675-3681. 
103. Taylor DE, Garner RS, Allan BJ. 1983. Characterization of tetracycline resistance 
plasmids from Campylobacter jejuni and Campylobacter coli. Antimicrobial Agents and 
Chemotherapy 24:930-935. 
104. Hao H, Yuan Z, Shen Z, Han J, Sahin O, Liu P, Zhang Q. 2013. Mutational and 
transcriptomic changes involved in the development of macrolide resistance in 
Campylobacter jejuni. Antimicrob Agents Chemother 57:1369-78. 
105. Corcoran D, Quinn T, Cotter L, Fanning S. 2006. An investigation of the molecular 
mechanisms contributing to high-level erythromycin resistance in Campylobacter. 
International Journal of Antimicrobial Agents 27:40-45. 
106. Zhang Q, Plummer PJ. 2008. Mechanisms of Antibiotic Resistance in Campylobacter, 
Campylobacter , Third Edition. American Society of Microbiology. 
107. Reece RJ, Maxwell A. 1991. DNA gyrase: structure and function. Crit Rev Biochem Mol 
Biol 26:335-75. 
108. Blondeau JM. 2004. Fluoroquinolones: mechanism of action, classification, and 
development of resistance. Survey of Ophthalmology 49:S73-S78. 
109. Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, Zhang Q. 2012. A Fluoroquinolone 
Resistance Associated Mutation in gyrA Affects DNA Supercoiling in Campylobacter 
jejuni. Frontiers in Cellular and Infection Microbiology 2. 
110. Zhang Q, Lin J, Pereira S. 2003. Fluoroquinolone-resistant Campylobacter in animal 
reservoirs: dynamics of development, resistance mechanisms and ecological fitness. 
Animal Health Research Reviews 4:63-72. 
111. Lin J, Michel LO, Zhang Q. 2002. CmeABC functions as a multidrug efflux system in 
Campylobacter jejuni. Antimicrob Agents Chemother 46:2124-31. 
112. Gibreel A, Wetsch NM, Taylor DE. 2007. Contribution of the CmeABC Efflux Pump to 
Macrolide and Tetracycline Resistance in Campylobacter jejuni. Antimicrobial Agents 
and Chemotherapy 51:3212-3216. 
113. Akiba M, Lin J, Barton YW, Zhang Q. 2006. Interaction of CmeABC and CmeDEF in 
conferring antimicrobial resistance and maintaining cell viability in Campylobacter 
jejuni. J Antimicrob Chemother 57:52-60. 
114. Ge B, McDermott PF, White DG, Meng J. 2005. Role of Efflux Pumps and 
Topoisomerase Mutations in Fluoroquinolone Resistance in Campylobacter jejuni and 
Campylobacter coli. Antimicrobial Agents and Chemotherapy 49:3347-3354. 
115. Webber MA, Piddock LJV. 2003. The importance of efflux pumps in bacterial antibiotic 
resistance. Journal of Antimicrobial Chemotherapy 51:9-11. 
30 
 
116. Jeon B, Wang Y, Hao H, Barton Y-W, Zhang Q. 2010. Contribution of CmeG to 
antibiotic and oxidative stress resistance in Campylobacter jejuni. Journal of 
Antimicrobial Chemotherapy 66:79-85. 
117. Pumbwe L, Piddock LJV. 2002. Identification and molecular characterisation of CmeB, a 
Campylobacter jejuni multidrug efflux pump. FEMS Microbiology Letters 206:185-189. 
118. Lin J, Sahin O, Michel LO, Zhang Q. 2003. Critical Role of Multidrug Efflux Pump 
CmeABC in Bile Resistance and In Vivo Colonization of Campylobacter jejuni. Infection 
and Immunity 71:4250-4259. 
119. Lin J, Cagliero C, Guo B, Barton Y-W, Maurel M-C, Payot S, Zhang Q. 2005. Bile Salts 
Modulate Expression of the CmeABC Multidrug Efflux Pump in Campylobacter jejuni. 
Journal of Bacteriology 187:7417-7424. 
120. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. 1995. Genes acrA and acrB 
encode a stress-induced efflux system of Escherichia coli. Mol Microbiol 16:45-55. 
121. Lin J, Akiba M, Sahin O, Zhang Q. 2005. CmeR Functions as a Transcriptional 
Repressor for the Multidrug Efflux Pump CmeABC in Campylobacter jejuni. 
Antimicrobial Agents and Chemotherapy 49:1067-1075. 
122. Grinnage-Pulley T, Zhang Q. 2015. Genetic Basis and Functional Consequences of 
Differential Expression of the CmeABC Efflux Pump in Campylobacter jejuni Isolates. 
PLOS ONE 10:e0131534. 
123. Guo B, Lin J, Reynolds DL, Zhang Q. 2010. Contribution of the Multidrug Efflux 
Transporter CmeABC to Antibiotic Resistance in Different Campylobacter Species. 
Foodborne Pathogens and Disease 7:77-83. 
124. Yan M, Sahin O, Lin J, Zhang Q. 2006. Role of the CmeABC efflux pump in the 
emergence of fluoroquinolone-resistant Campylobacter under selection pressure. Journal 
of Antimicrobial Chemotherapy 58:1154-1159. 
125. Hwang S, Zhang Q, Ryu S, Jeon B. 2012. Transcriptional Regulation of the CmeABC 
Multidrug Efflux Pump and the KatA Catalase by CosR in Campylobacter jejuni. Journal 
of Bacteriology 194:6883-6891. 
126. Luo N, Sahin O, Lin J, Michel LO, Zhang Q. 2003. In vivo selection of Campylobacter 
isolates with high levels of fluoroquinolone resistance associated with gyrA mutations 
and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 47:390-4. 
127. Cagliero C, Mouline C, Cloeckaert A, Payot S. 2006. Synergy between Efflux Pump 
CmeABC and Modifications in Ribosomal Proteins L4 and L22 in Conferring Macrolide 
Resistance in <em>Campylobacter jejuni</em> and <em>Campylobacter coli</em>. 
Antimicrobial Agents and Chemotherapy 50:3893-3896. 
128. Lomovskaya O, Bostian KA. 2006. Practical applications and feasibility of efflux pump 
inhibitors in the clinic—A vision for applied use. Biochemical Pharmacology 71:910-
918. 
31 
 
129. Kaatz GW. 2005. Bacterial efflux pump inhibition. Current opinion in investigational 
drugs (London, England : 2000) 6:191-198. 
130. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, 
Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ. 
2001. Identification and Characterization of Inhibitors of Multidrug Resistance Efflux 
Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy. 
Antimicrobial Agents and Chemotherapy 45:105-116. 
131. Mamelli L, Amoros J-P, Pagès J-M, Bolla J-M. 2003. A phenylalanine–arginine β-
naphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired 
resistance of Campylobacter to macrolides. International Journal of Antimicrobial Agents 
22:237-241. 
132. Sáenz Y, Ruiz J, Zarazaga M, Teixidó M, Torres C, Vila J. 2004. Effect of the efflux 
pump inhibitor Phe-Arg-β-naphthylamide on the MIC values of the quinolones, 
tetracycline and chloramphenicol, in Escherichia coli isolates of different origin. Journal 
of Antimicrobial Chemotherapy 53:544-545. 
133. Ribera A, Ruiz J, Jiminez de Anta MT, Vila J. 2002. Effect of an efflux pump inhibitor 
on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas 
maltophilia clinical isolates. Journal of Antimicrobial Chemotherapy 49:697-698. 
134. Chan YY, Tan TMC, Ong YM, Chua KL. 2004. BpeAB-OprB, a Multidrug Efflux Pump 
in <em>Burkholderia pseudomallei</em>. Antimicrobial Agents and Chemotherapy 
48:1128-1135. 
135. Martinez Al, Lin J. 2006. Effect of an Efflux Pump Inhibitor on the Function of the 
Multidrug Efflux Pump CmeABC and Antimicrobial Resistance in Campylobacter. 
Foodborne Pathogens and Disease 3:393-402. 
136. Sánchez P, Le U, Martínez JL. 2003. The efflux pump inhibitor Phe-Arg-β-
naphthylamide does not abolish the activity of the Stenotrophomonas maltophilia 
SmeDEF multidrug efflux pump. Journal of Antimicrobial Chemotherapy 51:1042-1045. 
137. Renau TE, Léger R, Flamme EM, She MW, Gannon CL, Mathias KM, Lomovskaya O, 
Chamberland S, Lee VJ, Ohta T, Nakayama K, Ishida Y. 2001. Addressing the stability 
of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin 
in Pseudomonas aeruginosa. Bioorganic & Medicinal Chemistry Letters 11:663-667. 
138. Renau TE, Léger R, Yen R, She MW, Flamme EM, Sangalang J, Gannon CL, 
Chamberland S, Lomovskaya O, Lee VJ. 2002. Peptidomimetics of Efflux Pump 
Inhibitors Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa. 
Bioorganic & Medicinal Chemistry Letters 12:763-766. 
139. Renau TE, Léger R, Filonova L, Flamme EM, Wang M, Yen R, Madsen D, Griffith D, 
Chamberland S, Dudley MN, Lee VJ, Lomovskaya O, Watkins WJ, Ohta T, Nakayama 
K, Ishida Y. 2003. Conformationally-restricted analogues of efflux pump inhibitors that 
potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic & 
Medicinal Chemistry Letters 13:2755-2758. 
32 
 
140. Watkins WJ, Landaverry Y, Léger R, Litman R, Renau TE, Williams N, Yen R, Zhang 
JZ, Chamberland S, Madsen D, Griffith D, Tembe V, Huie K, Dudley MN. 2003. The 
relationship between physicochemical properties, In vitro activity and pharmacokinetic 
profiles of analogues of diamine-Containing efflux pump inhibitors. Bioorganic & 
Medicinal Chemistry Letters 13:4241-4244. 
141. Jeon B, Zhang Q. 2009. Sensitization of Campylobacter jejuni to fluoroquinolone and 
macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux 
transporter. Journal of Antimicrobial Chemotherapy 63:946-948. 
142. Oh E, Zhang Q, Jeon B. 2013. Target optimization for peptide nucleic acid (PNA)-
mediated antisense inhibition of the CmeABC multidrug efflux pump in Campylobacter 
jejuni. Journal of Antimicrobial Chemotherapy 69:375-380. 
143. RAY A, NORDÉN B. 2000. Peptide nucleic acid (PNA): its medical and biotechnical 
applications and promise for the future. The FASEB Journal 14:1041-1060. 
144. Shakeel S, Karim S, Ali A. 2006. Peptide nucleic acid (PNA) — a review. Journal of 
Chemical Technology & Biotechnology 81:892-899. 
145. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim 
SK, Norden B, Nielsen PE. 1993. PNA hybridizes to complementary oligonucleotides 
obeying the Watson–Crick hydrogen-bonding rules. Nature 365:566-568. 
146. Nielsen PE, Haaima G. 1997. Peptide nucleic acid (PNA). A DNA mimic with a 
pseudopeptide backbone. Chemical Society Reviews 26:73-78. 
147. Nielsen PE. 2001. Peptide nucleic acid: a versatile tool in genetic diagnostics and 
molecular biology. Current Opinion in Biotechnology 12:16-20. 
148. Demidov VV, Potaman VN, Frank-Kamenetskil MD, Egholm M, Buchard O, Sönnichsen 
SH, Nlelsen PE. 1994. Stability of peptide nucleic acids in human serum and cellular 
extracts. Biochemical Pharmacology 48:1310-1313. 
149. McMahon BM, Mays D, Lipsky J, Stewart JA, Fauq A, Richelson E. 2002. 
Pharmacokinetics and Tissue Distribution of a Peptide Nucleic Acid After Intravenous 
Administration. Antisense and Nucleic Acid Drug Development 12:65-70. 
150. Demidov V, Frank-Kamenetskii MD, Egholm M, Buchardt O, Nielsen PE. 1993. 
Sequence selective double strand DNA cleavage by peptide nucleic acid (PNA) targeting 
using nuclease S1. Nucleic Acids Res 21:2103-7. 
151. Demers DB, Curry ET, Egholm M, Sozer AC. 1995. Enhanced PCR amplification of 
VNTR locus D1S80 using peptide nucleic acid (PNA). Nucleic Acids Res 23:3050-5. 
152. Perry-O'Keefe H, Yao XW, Coull JM, Fuchs M, Egholm M. 1996. Peptide nucleic acid 
pre-gel hybridization: an alternative to southern hybridization. Proc Natl Acad Sci U S A 
93:14670-5. 
153. Metcalf GAD, Shibakawa A, Patel H, Sita-Lumsden A, Zivi A, Rama N, Bevan CL, 
Ladame S. 2016. Amplification-Free Detection of Circulating microRNA Biomarkers 
from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between 
33 
 
Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis. 
Analytical Chemistry 88:8091-8098. 
154. Wang J, Palecek E, Nielsen PE, Rivas G, Cai X, Shiraishi H, Dontha N, Luo D, Farias 
PAM. 1996. Peptide Nucleic Acid Probes for Sequence-Specific DNA Biosensors. 
Journal of the American Chemical Society 118:7667-7670. 
155. Orum H, Nielsen PE, Egholm M, Berg RH, Buchardt O, Stanley C. 1993. Single base 
pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res 21:5332-6. 
156. Cerqueira L, Fernandes RM, Ferreira RM, Carneiro F, Dinis-Ribeiro M, Figueiredo C, 
Keevil CW, Azevedo NF, Vieira MJ. 2011. PNA-FISH as a new diagnostic method for 
the determination of clarithromycin resistance of Helicobacter pylori. BMC Microbiology 
11:101. 
157. Nielsen PE, Egholm M, Berg RH, Buchardt O. 1993. Peptide nucleic acids (PNAs): 
potential antisense and anti-gene agents. Anticancer Drug Des 8:53-63. 
158. Zaffaroni N, Villa R, Folini M. 2003. Therapeutic uses of peptide nucleic acids (PNA) in 
oncology. Letters in Peptide Science 10:287-296. 
159. Zorko M, Langel Ü. 2005. Cell-penetrating peptides: mechanism and kinetics of cargo 
delivery. Advanced Drug Delivery Reviews 57:529-545. 
160. Milletti F. 2012. Cell-penetrating peptides: classes, origin, and current landscape. Drug 
Discovery Today 17:850-860. 
161. Good L, Nielsen PE. 1998. Inhibition of translation and bacterial growth by peptide 
nucleic acid targeted to ribosomal RNA. Proceedings of the National Academy of 
Sciences 95:2073-2076. 
162. Bai H, You Y, Yan H, Meng J, Xue X, Hou Z, Zhou Y, Ma X, Sang G, Luo X. 2012. 
Antisense inhibition of gene expression and growth in gram-negative bacteria by cell-
penetrating peptide conjugates of peptide nucleic acids targeted to rpoD gene. 
Biomaterials 33:659-667. 
163. Kurupati P, Tan KSW, Kumarasinghe G, Poh CL. 2007. Inhibition of Gene Expression 
and Growth by Antisense Peptide Nucleic Acids in a Multiresistant β-Lactamase-
Producing Klebsiella pneumoniae Strain. Antimicrobial Agents and Chemotherapy 
51:805-811. 
164. Michael Rose AL, David Landman, and John Quale. 2019. In Vitro and In Vivo Activity 
of a Novel Antisense Peptide Nucleic Acid Compound Against Multidrug-Resistant 
Acinetobacter baumannii. Microbial Drug Resistance 25:961-965. 
165. Narenji H, Gholizadeh P, Aghazadeh M, Rezaee MA, Asgharzadeh M, Kafil HS. 2017. 
Peptide nucleic acids (PNAs): currently potential bactericidal agents. Biomedicine & 
Pharmacotherapy 93:580-588. 
166. Courtney CM, Chatterjee A. 2015. Sequence-Specific Peptide Nucleic Acid-Based 
Antisense Inhibitors of TEM-1 β-Lactamase and Mechanism of Adaptive Resistance. 
ACS Infectious Diseases 1:253-263. 
34 
 
167. Mu Y, Shen Z, Jeon B, Dai L, Zhang Q. 2013. Synergistic Effects of Anti-CmeA and 
Anti-CmeB Peptide Nucleic Acids on Sensitizing Campylobacter jejuni to Antibiotics. 
Antimicrobial Agents and Chemotherapy 57:4575-4577. 
35 
 
CHAPTER 3.    INHIBITION OF THE CmeABC MULTIDRUG EFFLUX PUMP BY 
PEPTIDE NUCLEIC ACID PREVENTS THE EMERGENCE OF SPONTANEOUS 
FLUOROQUINOLONE RESISTANT MUTANTS IN CAMPYLOBACTER JEJUNI IN 
VITRO 
Kritika Singh, Lei Dai, Qijing Zhang 
Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary 
Medicine, Iowa State University, Ames IA 50011 USA 
Modified from a manuscript to be submitted to Antimicrobial Agents and Chemotherapy 
 
Abstract 
Campylobacter jejuni is a major enteric pathogen that has become resistant to clinically 
important antibiotics. The CmeABC efflux pump is one of the major resistance mechanisms that 
has been known to work in synergy with point mutations in the gyrA gene to confer high-level 
fluoroquinolone (FQ) resistance, which develops rapidly when Campylobacter is exposed to FQ 
antibiotics that are used for clinical therapy of campylobacteriosis. Previously it has been shown 
that peptide nucleic acid (PNA CmeA1) specifically targeting the predominant drug efflux 
transporter CmeABC inhibited the expression of this efflux pump and sensitized Campylobacter 
to clinically important antibiotics including FQs.  In this study, the CmeA1 PNA was evaluated 
to inhibit the emergence of fluoroquinolone resistant mutants. A FQ-susceptible Campylobacter 
jejuni strain was subjected to treatments with ciprofloxacin, with or without the PNA. After 48 
hrs, the culture treated with ciprofloxacin alone developed FQ-resistant mutants, while the 
culture treated with ciprofloxacin and the PNA showed no growth. To further quantify the 
difference, growth kinetics were measured at different time points. Once ciprofloxacin was 
added, the colony forming units (CFUs) of the culture without PNA decreased, but between 12 
and 24 hrs, FQ-resistant mutants emerged and the CFUs started to increase. On the contrary, the 
CFUs of the culture treated with ciprofloxacin and PNA steadily decreased and were no longer 
36 
 
detectable after 12 hrs, indicating that no resistant mutants emerged in the culture. These results 
show that the anti-CmeABC PNA potentiates the killing effect of ciprofloxacin and inhibits the 
emergence of ciprofloxacin resistant mutants in C. jejuni. 
 
Introduction 
Campylobacter has been recognized as a leading cause of bacterial food-borne disease. 
According to the Centers for Disease Control (CDC), there are over 1.3 million cases of 
campylobacteriosis each year in the United States (1). Worldwide, Campylobacter infections are 
estimated to cause 400-500 million cases of diarrhea each year (2). A major source of infection is 
consumption of contaminated animal food like poultry and raw milk. Clinical symptoms can 
range from mild to severe, including bloody diarrhea, nausea, fever, headache and abdominal 
pain. Extra-gastrointestinal complications may also develop, which include Guillain-Barré 
syndrome (GBS) (3-5), Miller Fisher syndrome (6), bacteremia and septicemia as well as 
reactive arthritis (7, 8), meningitis, and cardiovascular complications (9). When clinical therapy 
is needed, fluoroquinolones and macrolides are the first line of antibiotics used to treat 
campylobacteriosis; however, resistance to these antibiotics, particularly to fluoroquinolones, has 
increased drastically over the past decades (10, 11). 
Campylobacter possesses multiple mechanisms for antibiotic resistance. It is intrinsically 
resistant to novobiocin, bacitracin, vancomycin, and polymyxins due to lack of target sites or low 
affinity for them. Campylobacter is also able to alter membrane permeability to restrict the 
uptake of antibiotics like macrolides and β-lactams (12). Synthesizing enzymes to degrade or 
modify antibiotics is another common resistance mechanism and the resistance genes are 
normally obtained via horizontal gene transfer (13, 14). Campylobacter may also protect or 
modify the drug target by acquiring various resistance genes or through mutations in existing 
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genes (15-17).  For example, point mutations in the quinolone resistance-determining region 
(QRDR) of the gyrA gene is responsible for fluroquinolone resistance in C. jejuni and C. coli. 
Fluoroquinolone antibiotics bind to DNA gyrase while it is attached to the DNA to form a stable 
complex, which traps the enzyme in place leading to double stranded breaks in the DNA and 
results in bacterial death. Certain point mutations in gyrA result in the inability of 
fluoroquinolones to bind to their target, leading to resistance. Additionally, these resistance-
conferring mutations do not seem to alter the function of DNA gyrase, which means there isn’t a 
fitness cost associated with the acquisition of the resistance (18-21), but it is usually the case 
with macrolide resistance (22). 
One of the primary mechanisms of antimicrobial resistance in Campylobacter is 
antibiotic efflux pumps such as CmeABC (23). The CmeABC efflux pump is encoded by a 
three-gene operon (cmeA, cmeB, and cmeC) and is made of three proteins; an inner membrane 
transporter (CmeB), a periplasmic fusion protein (CmeA), and an outer membrane protein 
(CmeC). CmeABC confers resistance to structurally and functionally diverse antibiotics and 
toxic compounds (24). Furthermore, it works in synergy with the other resistance mechanisms 
mentioned above (17, 25).  It has also been shown that overexpression of CmeABC in 
Campylobacter significantly increases the frequency of emergence of fluoroquinolone-resistant 
mutants under selection pressure (26). The synergistic effect of efflux pumps and the acquisition 
of resistance genes and mutations poses a significant challenge for clinical therapy. This is 
especially obvious with fluoroquinolone antibiotics as resistance to this class of antibiotics 
occurs during clinical treatment due to spontaneous mutations in gyrA and the synergistic 
function of CmeABC. Thus, inhibition of CmeABC is a promising strategy to reduce the 
emergence of fluoroquinolone resistant mutants as well as potentiate the efficacy of antibiotics.  
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One way to inhibit the function of CmeABC is to use antisense peptide nucleic acids 
(PNA) to inhibit the expression of this efflux pump. PNA is a synthetic polymer composed of N‐
(2‐aminoethyl) glycine units with nucleobases attached to the glycine nitrogen via carbonyl 
methylene linkers. It can, therefore, base pair with DNA and RNA with high specificity (27-30). 
PNA is resistant to enzymatic degradation and remains in tissues for long periods of time (31, 
32). These properties of high specificity of binding and stability in the presence of proteolytic 
enzymes make PNA uniquely suitable for use as an antisense therapeutic. Previously, it has been 
shown that PNA designed to target cmeABC can significantly reduce the expression of the efflux 
pump and consequently decrease MICs of antibiotics (33). Particularly, the PNA sequence 
spanning the ribosome binding site (RBS) of cmeA was the most successful at inhibiting 
expression of the cmeABC efflux pump (34).  
Despite this progress, it remains to be determined whether the PNA against CmeABC can 
inhibit the emergence of fluoroquinolone resistant mutants in Campylobacter during antibiotic 
treatment. Since the PNA specifically inhibits the expression of cmeABC, we hypothesized that 
use of PNA along with a fluoroquinolone antibiotic would prevent the emergence of 
fluoroquinolone resistant mutants. To test this hypothesis, we conducted antibiotic treatment 
experiments in the presence or absence of PNA and compared the rates of emergence of 
fluoroquinolone resistant mutants using an in vitro culture system. 
 
Materials and Methods 
Bacterial Strains and Growth Conditions  
C. jejuni strains were cultured microaerobically in a gas chamber (AnaeroPack, 
ThermoFisher) filled with 5% O2, 10% CO2 and 85% N2 on Mueller-Hinton (MH) agar or in 
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Mueller-Hinton (MH) broth at 42°C. All strains are preserved as 30% glycerol stock at -80°C. 
The strains used in this study are listed in the table below.  
Table 1. Bacterial strains used in this study and the minimum inhibitory concentrations of 
ciprofloxacin. 
Bacterial Strain Genotype or Phenotype MIC for 
Cipro 
Reference 
NCTC 11168 C. jejuni reference strain 0.063 µg/ml (35) 
11168W199G Naturally occurring variant of 11168 
with point mutation in mutY 
0.063 µg/ml (36) 
CT6:16L C. jejuni isolate from commercial 
turkey 
0.063 µg/ml (37) 
CT7:20C1 C. jejuni isolate from commercial 
turkey 
0.063 µg/ml (37) 
11168W199GCRM1 
- 
11168W199GCRM10 
Ciprofloxacin resistant mutants 
generated by applying antibiotic 
selection pressure on 11168W199G 
4 µg/ml This Study 
 
Antimicrobial Susceptibility Tests  
Ciprofloxacin, a fluoroquinolone antibiotic, used in this study was purchased from 
Sigma-Aldrich Co. LLC. Its MIC was determined using the standard broth microdilution method 
as previously described (23). Briefly, two-fold serial dilutions of ciprofloxacin were made in MH 
broth in wells of 96-well round bottomed culture plates.  The first well contained only MH broth 
as a no-antibiotic control. Each antibiotic dilution was 50 µl in volume. The C. jejuni inoculum 
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was prepared by growing a fresh culture overnight on MH agar plates. The culture was then 
resuspended in MH broth to obtain OD 0.1 at 600 nm. Subsequently it was diluted 100-fold to 
achieve approximately 106 CFU/ml., and 50 µl of the cell suspension was then added to each of 
the wells containing various concentrations of antibiotics. The plates were incubated at 42°C for 
24 hrs in a microaerobic chamber. Each MIC test was run in duplicates. 
To evaluate the effect of PNA on potentiating the effect of antibiotics, the MIC assay was 
performed in parallel with or without the CmeA1 PNA. The C. jejuni inoculum was prepared as 
described above and split into two parts: one with PNA (2 µM for 11168 and 1 µM for CT 
strains) and the other without PNA. After 30 mins, the cell inocula were added to the 96-well 
plates containing various ciprofloxacin dilutions. The plates were incubated at 42°C for 24 hrs 
microaerobically.   
PNA Preparation  
The CmeA1 PNA was selected for this study based on the fact that it was the most 
effective in inhibition of cmeABC (34). The PNA targets the ribosome-binding site (RBS) of 
cmeA. The PNA was synthesized and conjugated to a penetrating peptide (CPP) by PNA BIO 
INC (Newbury Park, CA, USA), resulting in the CPP-PNA construct: KFFKFFKFFK-
tgccttgaaaaa. A second control PNA, not targeting any specific sequences, in Campylobacter was 
also synthesized in the same way: KFFKFFKFFK-acacacacacac. Each PNAs was received as a 
lyophilized powder, which was reconstituted using sterilized dd.H2O to make a stock solution of 
200 µM and aliquoted into tubes for storage at -20°C. 
Qualitative Determination of Emergence of Ciprofloxacin Resistant Mutants  
A qualitative growth test was performed with antibiotic selection pressure to measure the 
emergence of ciprofloxacin resistant mutants in the presence or absence of the CmeA1 PNA. A 
106 CFU/ml starting culture was prepared from C. jejuni 11168W199G. This strain was used in 
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place of C. jejuni NCTC 11168 as it has a point mutation in the mutY gene that increases its 
mutation frequency by 100-fold when compared to wild-type 11168 (36). This gives rise of a 
large dynamic range of resistant mutant emergence that can be measured easily in culture media. 
A fresh culture of 11168W199G was divided into 5 different treatment groups as listed below: 
• Treated with ciprofloxacin (1 µg/ml) 
• Treated with ciprofloxacin (1 µg/ml) and the CmeA1 PNA (2 µM) 
• Treated with the CmeA1PNA (2 µM) only  
• Treated with ciprofloxacin (1 µg/ml) and the control PNA (2 µM) 
• Treated with the control PNA (2 µM) only  
The appropriate amount of PNA was added to the cultures. After 30 min incubation, 
ciprofloxacin was added and 100 µl of the mixture was distributed to a well of a 96-well plate. 
The ciprofloxacin-only treatment had 16 wells, while every other treatment had 8 wells. The 
plates were incubated at 42 °C microaerobically in a gas chamber. At 24 and 48 hrs of 
incubation, visual observation of growth indicated by turbidity change was conducted and 
images of the growth were taken. To confirm growth or lack thereof, at the end of the experiment 
(after 48 hours of incubation), the cultures in the wells were spread onto MH agar plates with or 
without ciprofloxacin (1 µg/ml) and bacterial growth on plates was observed after 24 hrs of 
incubation. 
Quantitative Determination of the Emergence of Ciprofloxacin Resistant Mutants  
Growth kinetics of C. jejuni in the presence of ciprofloxacin with or without PNA were 
conducted in culture media to determine the frequencies of emergence of ciprofloxacin resistant 
mutants. The starting culture (106 CFU/ml) of C. jejuni 11168W199G was prepared and divided 
into 3 treatment groups, including ciprofloxacin-only treated group, ciprofloxacin and 
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CmeA1PNA treated group, and CmeA1PNA-only treated group. The cultures of various 
treatments were grown at 42 °C microaerobically on 96-well round bottomed culture plates. Each 
treatment group had 15 wells and at each of the time points (0, 6, 12, 24 and 48 hrs), cultures 
collected from 3 wells were used to measure the colony forming units (CFUs). The CFUs were 
determined using the drop plating method described below.   
To further confirm the effect of the CmeA1 PNA in reducing the emergence of 
fluoroquinolone resistant mutants, an additional growth kinetics test was conducted using culture 
tubes instead of 96-well plates to allow continuous sampling of the same cultures at different 
time points. The starting culture (106 CFU/ml) was prepared and divided into 3 treatment groups: 
ciprofloxacin-only treated group, ciprofloxacin and CmeA1 PNA treated group, and 
CmeA1PNA-only treated group.  The tubes were incubated at 42 °C microaerobically. At 0, 6, 
12, 24, and 48 hrs, 100 µl of culture was collected from each tube to determine the CFU 
numbers. This experiment was performed in triplicates, i.e. 3 tubes were used for each treatment 
condition. The CFU counts were determined by using the drop plating method as described 
below. 
Drop Plating Method for CFU Enumeration  
C. jejuni cultures collected from different treatment groups and time points were diluted 
to make 10-fold dilution series. From each dilution, three 10 µl drops were plated on an MH agar 
plate, 7 dilutions along with the original were plated in this manner to obtain the best dilution for 
counting single colonies. The colonies were counted, and the CFU/ml of the original culture was 
calculated based on the dilution factors. 
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Statistical Analysis  
An unpaired student’s t test was used to compare the average Campylobacter CFU/ml 
between treatment groups. P values of < 0.05 were deemed to be statistically significant. 
GraphPad prism 8 software (GraphPad Software San Diego, CA) was used to generate the 
graphs. 
Determination of gyrA Mutations  
In Campylobacter, fluoroquinolone resistance is conferred by point mutations in the gyrA 
gene in concurrence with the CmeABC efflux pump (38). To confirm the mechanism of 
fluroquinolone resistance in this study and for determination of the point mutations in the 
quinolone resistance-determining region (QRDR) of gyrA, primers GyrAF1 (5′-
CAACTGGTTCTAGCCTTTTG-3′) and GyrAR1 (5′-AATTTCACTCATAGCCTCACG-3′) 
were designed according to previously published work (21). The PCR conditions included initial 
heating to 95°C for 5 mins (denaturation) and followed by 35 cycles of 95°C for 45s, 52°C for 
30s, and 72°C for 60s. Final extension was done at 72°C for 7mins. All PCR products were 
purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) and then sequenced 
at the DNA Core Facility of Iowa State University using an Applied Biosystems 3730xl DNA 
analyzer. 
 
Results 
Qualitative Test Displayed a Reduction in the Emergence of Ciprofloxacin Resistant 
Mutants 
C. jejuni 11168W199G is a known mutator strain that has a higher mutation frequency 
for fluoroquinolone resistance (100-fold higher than 11168) (36), which provides an efficient 
system for measuring the effect of PNA. As shown in Figure 1, there was no visible growth in 
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the wells treated with either ciprofloxacin or both ciprofloxacin and PNA at 24 hrs of incubation, 
indicating that ciprofloxacin alone was able to kill most of the C. jejuni 11168W199G cells 
initially. Bacterial growth was obvious in the wells treated with PNA alone, suggesting PNA 
itself did not kill C. jejuni. At 48 hrs of incubation, 60% (10/16) of the ciprofloxacin treated 
wells showed re-growth due to development of fluoroquinolone-resistant mutants, which was 
confirmed by growth on MH agar plates with and without ciprofloxacin (1µg/ml). The cultures 
from the visually clear wells did not show growth on either plate, while the wells that were turbid 
demonstrated bacterial growth on both MH agar plates with and without ciprofloxacin (1µg/ml). 
Notably, there was no visible bacterial growth in all the wells co-treated with ciprofloxacin and 
the CmeA1 PNA, which was further confirmed by plating the cultures on MH agar plates as 
mentioned above. Half of the wells (4/8) co-treated with ciprofloxacin and the control PNA wells 
also showed emergence and growth of ciprofloxacin resistant mutants, indicating the control 
PNA did not potentiate the antibiotic or reduce the emergence of resistant mutants. The wells 
with visible growth grew on both MH agar plates with and without ciprofloxacin confirming that 
the growth in the wells was from ciprofloxacin resistant colonies.  
The wells treated with PNA (CmeA1 PNA and control PNA) alone showed uniformed 
growth both at 24 and 48 hrs, and at the end of the experiment when cultures were spread on 
plates with or without ciprofloxacin (1µg/ml), growth was only observed on the plates without 
ciprofloxacin, indicating that the culture from the PNA-only treatments remained susceptible to 
ciprofloxacin. These results indicate that the CmeA1 PNA, not the control PNA, synergized with 
ciprofloxacin in killing C. jejuni and prevented the development of fluoroquinolone-resistant 
mutants during antibiotic treatment. 
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Figure 1. Qualitative test to determine the effectiveness of the CmeA1 PNA at inhibition of the 
emergence of fluoroquinolone-resistant mutants in 11168W199G. 
Quantitative Measurement of Mutant Reduction by PNA  
Based on the result described above, we further conducted detailed analysis of mutant 
emergence by measuring CFU numbers at different time points and the data are shown in Figure 
2. At the beginning of the treatment, all treatment groups had similar CFU numbers. At 6 hr, the 
ciprofloxacin-treated and the co-treated cultures showed significant reduction in CFUs, while the 
PNA-only treated culture showed growth and remained growing until the end of the experiment. 
At 12 hr, the ciprofloxacin and PNA co-treated cultures showed no CFU growth and remained 
this status until the end of the experiment. The CFUs in the ciprofloxacin-only treated cultures 
continued to decline at 12 hr however it was not as drastic as the CFUs in the ciprofloxacin and 
PNA co treated cultures. At 24 hr, two of the 3 wells showed no CFU, while 1 of the three 
showed CFU re-growth, indicating the emergence of resistant mutants in the well. At 48 hr, 
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however, all three wells of the ciprofloxacin-only treated cultures showed high CFU numbers, 
indicating the population expansion of ciprofloxacin-resistant mutants.  
 
Figure 2. Quantitative determination of CFU counts in cultures with different treatments. The 2 
treatment groups (ciprofloxacin only and ciprofloxacin + PNA) were compared at each time 
point via statistical analysis. * and **** indicate statistically significant difference (p <0.05 and 
p < 0.0001, respectively). ns indicates not significant. 
Randomly picked colonies at each time point were assayed for growth or lack of growth 
on MH plates containing ciprofloxacin (1µg/ml) agar plates to confirm the population change 
(Table 2). The colonies from the ciprofloxacin-only treated group shifted from susceptible to 
resistant during the course of the experiment and the shift occurred at the 12-hr time point. The 
colonies from the ciprofloxacin and PNA co-treated group remained susceptible until all 
Campylobacter cells were killed. Colonies from the PNA-only treated group remained 
susceptible throughout the experiment. These results correspond with the CFU trends shown in 
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Figure 2Error! Reference source not found. and confirmed the emergence of ciprofloxacin-r
esistant mutants in the cultures treated with ciprofloxacin.  
Table 2. Growth of randomly picked colonies from each treatment group on MH agar containing 
ciprofloxacin (1 µg/ml). 
Time Points PNA PNA + Ciprofloxacin Ciprofloxacin 
0hr 0/5 0/10 0/10 
6hr 0/5 0/10 0/10 
12hr 0/5 No Colonies 10/10 
24hr 0/5 No Colonies 10/10 
48hr 0/5 No Colonies 10/10 
 
Quantitative Test Confirmed Elimination of Emergence of Ciprofloxacin Resistant 
Mutants by PNA  
To further confirm the potentiating effect of the CmeA1 PNA on ciprofloxacin, an 
additional experiment using continuous sampling of the same cultures was performed. Three 
replicates were used for each treatment and the results are shown in Figure 3. Ciprofloxacin 
rapidly reduced the CFUs in the treated groups. By 12 hrs, the co-treatment with PNA and 
ciprofloxacin had eliminated Campylobacter from 2/3 of the replicates, while the ciprofloxacin-
only treated cultures remained CFUs at a low level. At 24 hrs, the ciprofloxacin-only treated 
cultures showed re-growth of CFUs, indicating the development and growth of resistant mutants. 
The CFUs in these cultures continued to increase, and by 48 hrs, the CFU counts are as high as 
the PNA-only treated cultures. On the contrary, no CFUs were detected in the cultures co-treated 
with ciprofloxacin and PNA at 24 and 48 hrs. The remaining cultures of this treatment at 48 hrs 
were further plated onto MH plates containing ciprofloxacin (1µg/ml), and no colonies were 
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detected, confirming that co-treatment with ciprofloxacin and PNA eliminated the emergence of 
fluoroquinolone-resistant mutants. 
 
Figure 3. Quantitative measurement of CFUs in cultures of various treatments at different time 
points. The 2 treatment groups (ciprofloxacin-only and ciprofloxacin plus PNA) were compared 
at each time point via statistical analysis to determine the differences in the CFU counts. *, *** 
and **** indicate statistically significant differences (p <0.05, p < 0.001 and p < 0.0001, 
respectively). 
At each time point, a single colony was randomly picked from each replicate from the 
MH agar plates on which the CFU enumeration was done. These colonies were examined for 
growth on MH plates containing 1 µg/ml ciprofloxacin. As shown in Table 3, at 0 and 6 hrs, the 
colonies collected from all treatment groups were susceptible to ciprofloxacin (not able to grow 
on the plates containing 1 µg/ml ciprofloxacin). At 12 hrs, one colony collected from the PNA 
and ciprofloxacin co-treated group was susceptible to ciprofloxacin, while 2/3 colonies collected 
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from the ciprofloxacin-only group were able to grow on the ciprofloxacin-containing plates. At 
24 and 48hours, all the colonies collected from the ciprofloxacin-only treated group were 
resistant to ciprofloxacin, while no colonies were available in the PNA and ciprofloxacin co-
treated group for testing as all the Campylobacter had been eliminated. The PNA-only treated 
group had all ciprofloxacin susceptible Campylobacter at all time points.  
Table 3. Growth of randomly picked colonies from each treatment group on MH agar plates 
containing ciprofloxacin (1µg/ml). 
Time Points PNA only PNA + Cipro Cipro only 
0hr 0/3 0/3 0/3 
6hr 0/3 0/3 0/3 
12hr 0/3 0/2 2/3 
24hr 0/3 No Colonies 3/3 
48hr 0/3 No Colonies 3/3 
 
Identification of Point Mutations in gyrA in Ciprofloxacin-Resistant Mutants.  
Ten ciprofloxacin-resistant mutants were randomly selected from ciprofloxacin-only 
treated group for PCR and sequence analysis. They were amplified by PCR for the QRDR region 
of the gyrA gene and the PCR products were sequenced. All 10 colonies displayed the known G 
to T point mutation at the 268 position that is associated with fluoroquinolone resistance in C. 
jejuni (36). 
Discussion 
C. jejuni is known to develop resistance to fluoroquinolone antibiotics swiftly in response 
to treatment with this class of antibiotics (36, 39). This happens both in culture media and in 
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animal hosts, and has contributed to the global prevalence of fluoroquinolone-resistant 
Campylobacter (21, 40-44). Given the importance of fluoroquinolones in clinical therapy for 
campylobacteriosis, it is necessary to develop strategies to prevent the development of 
fluoroquinolone resistance. In this study, we demonstrated that the CmeA1 PNA specifically 
targeting the CmeABC efflux pump is able to prevent the emergence of fluoroquinolone resistant 
mutants in culture media. This conclusion is supported by the results obtained from the 
qualitative test and the growth kinetics experiments (Figures 1-3) as well as confirmatory testing 
of randomly selected colonies (Tables 1-3). Additionally, we showed that the CmeA1 PNA 
enhanced the killing effect of ciprofloxacin as evidenced by the more rapid decline of CFU 
numbers in the cultures co-treated by ciprofloxacin and PNA compared with the ones treated 
only with ciprofloxacin. These finding suggest the potential of the CmeA1 PNA as an effective 
adjunct therapy for clinical use of fluoroquinolone antibiotics. 
The use of a mutator strain of 11168 in the experiments allowed us to measure the 
dynamic changes of resistant mutant development. The qualitative test (Figure 1) not only 
demonstrated the potentiating effect of the CmeA1 PNA on ciprofloxacin, but also confirmed 
that this effect is specific for the PNA designed against CmeABC efflux pump (CmeA1 PNA) 
and was not due to an unspecific side effect of any PNA molecule, because the control PNA was 
not able to eliminate the emergence of fluoroquinolone resistant mutants. In fact, the treatment 
with ciprofloxacin and the control PNA yielded similar results to the ones treated by 
ciprofloxacin only (Figure 1). Therefore, we can conclude that PNA itself did not affect 
Campylobacter growth under the concentration used in this study.  
Measuring CFU counts at different time points provided more details on kinetics of 
resistant mutant development. Ciprofloxacin and PNA co-treatment resulted in continuous 
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decline of live CFUs until all Campylobacter cells were killed, which happened around 12 or 24 
hrs after the initiation of the treatment (Figures 2 and 3). On the contrary ciprofloxacin-only 
treatment produced an initial decline of CFUs, but re-growth was apparent after 12 hrs due to 
emergence of resistant mutants. It should be pointed out that the emergence of fluoroquinolone-
resistant mutants is a spontaneous process, which could explain that only some of the wells/tubes 
treated with ciprofloxacin developed resistant mutants initially although all the cultures were 
repopulated by resistant mutants at the end of the experiments (Figures 2 and 3).  
The emergence of ciprofloxacin-resistant mutants during the treatments was confirmed 
by plating the cultures on ciprofloxacin-containing plates and by testing colonies randomly 
selected at different time points (Tables 2 and 3).  Additionally, PCR and sequencing analysis 
revealed the known mutation in the QRDR of gyrA that confers the resistance to 
fluoroquinolones. It should be mentioned that the 11168W199G strain used in this study has a 
defective mutY and tends to generate G to T mutations (36). In natural isolates, there are other 
mutations in gyrA that also contribute to fluroquinolone resistance such as the C257T mutation 
(20). In either case, GyrA mutation alone are not sufficient to confer high-level resistance to 
fluoroquinolones. These mutations work synergistically with the CmeABC efflux pump to 
achieve high MICs of ciprofloxacin (26, 38, 41). 
Small molecule inhibitors, such as Efflux Pump Inhibitors (EPIs), can be used to interfere 
with the activity of the efflux pump; however, these are known to be inconsistent with their 
inhibition capabilities (45-47). Furthermore, the concentrations required for inhibition are highly 
toxic in vivo (48). PNA on the other hand has already been used in mammalian studies and did 
not show any toxic effects (49, 50). This characteristic combined with the high specificity of 
target inhibition and resistance to enzymatic degradation makes PNA a promising candidate for 
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an adjunct therapeutic. As shown in three independent experiments (Figures 1-3), the CmeA1 
PNA was able to prevent the emergence of fluoroquinolone resistant mutants. Since CmeABC is 
known to work in synergy with other resistance mechanisms to confer high MICs (11, 17, 24), it 
is reasonable to say that inhibiting CmeABC by the CmeA1 PNA would increase the 
susceptibility of the resistant mutants to ciprofloxacin and leads to complete killing of the 
mutants by the antibiotic. Altogether, the results from this study demonstrate the potentiating 
effect of the CmeA1 PNA on ciprofloxacin against C. jejuni and provide a strong rationale for 
conducting in vivo studies to assess the efficacy of the PNA as an adjunct therapy. 
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Abstract 
Campylobacter jejuni is the leading cause of bacterial gastroenteritis worldwide and is 
increasingly resistant to fluoroquinolone (FQ), which are clinically used antibiotics for the 
treatment of campylobacteriosis. FQ resistance spontaneously occur in C. jejuni and our previous 
work showed that antisense peptide nucleic acid (PNA) targeting the CmeABC efflux pump 
prevented the emergence of FQ-resistant mutants in C. jejuni when treated with ciprofloxacin in 
culture media. However, the efficacy of the PNA in potentiating the antibiotic under in vivo 
conditions has not been evaluated. In this study, chickens infected by FQ-susceptible C. jejuni 
were subjected to treatment with enrofloxacin (50 ppm in drinking water) with or without the 
PNA administered via oral gavage. In three independent trials, FQ-resistant Campylobacter 
consistently emerged in the chickens treated with enrofloxacin, and the PNA, when given at a 
dose of  2 µM per bird, initially reduced the development of FQ-resistant mutants but did not 
eliminate the mutants in the birds treated with enrofloxacin. Doubling the daily dosing of PNA 
did not further increase the efficacy of the PNA. PNA alone, when given at the same dose, did 
not show apparent toxicity to the birds and did not affect Campylobacter colonization and 
development of FQ-resistant mutants in chickens. These results demonstrate the potential of the 
PNA as an adjunct therapy to potentiate FQ antibiotics in reducing the development of FQ-
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resistant Campylobacter. Further studies are needed to optimize the dose and treatment scheme 
of antibiotic and PNA to eliminate the emergence of FQ-resistant mutants. 
 
Introduction 
Campylobacter jejuni is a gram negative, curved rod shaped, and thermophilic bacterium. 
It colonizes the intestinal mucosa of most warm-blooded animals, including all food-producing 
animals and the human host. C. jejuni is especially prevalent in avians, such as chickens, turkeys, 
quails, ducks, and wild birds (1). In these animals, C. jejuni is generally considered a 
commensal, but in humans it causes acute gasteroenteritis (2, 3). In fact, C. jejuni is one of the 
most common causes of bacterial food-borne disease. According to the CDC, there are over 1.3 
million cases of campylobacteriosis ever year in the United States (4). Worldwide, 
Campylobacter infections are estimated to be responsible for 400-500 million cases of diarrhea 
each year (5). C. jejuni is known to be able to survive the poultry meat processing and 
throughout the food supply chain, which constitutes a major source of infection for sporadic 
cases of campylobacteriosis in humans.  On the other hand, consumption of raw milk is a main 
risk factor for outbreaks of human Campylobacter infections (3, 6). 
For clinical treatment of human campylobacteriosis, fluoroquinolones and macrolides are 
the first choice of antibiotics (7, 8). Unfortunately, Campylobacter has become increasingly 
resistant to clinically important antimicrobials over the years (9-11). The World Health 
Organization (WHO) has listed antibiotic resistant Campylobacter as a pathogen of high concern 
that urgently needs novel therapeutic strategies to combat infection (12). Campylobacter has 
developed multiple mechanisms for antibiotic resistance, such as target modification by 
acquiring point mutations and target protection by acquiring resistance genes through horizontal 
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gene transfer (e.g tetO that confers tetracycline resistance) (10, 11). A major mechanism for 
multi-drug resistance in Campylobacter is the CmeABC efflux pump (13). 
The CmeABC efflux pump belongs to the resistance-nodulation-division (RND) family 
of membrane transporters and is used by Campylobacter to extrude toxic compounds, such as 
bile and antimicrobials (14). CmeABC works synergistically with other resistance mechanisms 
and confers resistance to structurally diverse antibiotics. It has been shown that CmeABC 
increases the emergence of spontaneous fluoroquinolone-resistant mutants in Campylobacter as 
inactivation of the cmeABC operon led to significant decrease in the detected mutant frequency 
(15). Owing to its key function in bile resistance, CmeABC is essential for Campylobacter 
colonization in the intestinal tract of an animal host (14).  Given the key role of CmeABC in 
antimicrobial resistance and gut colonization, inhibition of this efflux pump is a promising 
strategy for combating antibiotic-resistant Campylobacter (16). 
Campylobacter is a zoonotic pathogen and is therefore exposed to antibiotics used in both 
animal production and human medicine. Ciprofloxacin is a fluoroquinolone antibiotic and is 
commonly used to treat bacterial infections in human patients.  Fluoroquinolones were also used 
on poultry farms (for treatment of other bacterial infections such as colibacillosis) until 2005, 
when they were banned in the United States (17). The decision to ban fluroquinolones on poultry 
farms was incited due to the drastic rise of fluoroquinolone resistant Campylobacter since the use 
of the antibiotic in poultry (18, 19). This had raised a major public health concern as 
fluoroquinolone resistant Campylobacter can be transmitted to humans via contaminated retail 
poultry meat, resulting in campylobacteriosis that is less receptive to fluoroquinolone therapy 
(20). Multiple studies have shown that the use of fluoroquinolones in broiler chickens selects 
fluoroquinolone-resistant Campylobacter from originally fluoroquinolone-susceptible 
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Campylobacter, and fluoroquinolone-resistant Campylobacter rapidly appeared during the 
treatment, resulting in replacement of the susceptible Campylobacter population in the treated 
birds (21, 22). Since the emergence of fluoroquinolone resistance from susceptible 
Campylobacter in chickens treated with enrofloxacin is well documented, chicken is an ideal 
animal model to test if inhibition of the CmeABC efflux pump reduces the emergence of 
fluoroquinolone resistance. 
In general, there are two ways to inhibit bacterial efflux: blocking its function or 
inhibiting its expression (23, 24). Efflux pump inhibitors (EPIs) are molecules that specifically 
block the efflux function of MDR efflux pumps. This can be accomplished by physically 
obstructing the efflux pump channel or by competing with the natural substrates. EPIs could also 
inhibit efflux activity by altering the pump assembly or destroying its energy mechanism (25). 
EPIs have been attempted to inhibit the CmeABC efflux pump in Campylobacter. Phenyl-
arginine-β-naphthylamide (PAβN) and 1-(1-naphthylmethyl)-piperazine (NMP) are 2 EPIs that 
have been used to lower the minimum inhibitory concentrations (MICs) of fluoroquinolones and 
macrolides (26-28).  The results from different studies varied greatly and were not consistent. 
Furthermore, none of these EPIs have been tested in vivo as the previous studies were conducted 
only in culture media. Additionally, EPIs are generally toxic at the levels required for inhibition 
and many modifications made to the structures to reduce their toxicity also resulted in loss of 
inhibitory effects on efflux pumps and reduce stability in animal serum (24, 29-33). Thus, safe 
and efficacious EPIs are yet to be developed as an adjunct therapy for antibiotic therapy.  
Peptide nucleic acids (PNA) on the other hand can be designed to inhibit the expression 
of efflux pumps instead of blocking its function. PNAs are synthetic polymers, composed of N‐
(2‐aminoethyl) glycine units with nucleobases attached to the glycine nitrogen via carbonyl 
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methylene linkers, and have been successfully used as a drug in mammals without any toxic 
effects (34, 35). PNA has the ability to base pair specifically with DNA and RNA due to the 
nucleobases in the composition that mimic nucleic acid structure (36, 37). This characteristic 
allows PNA to target expression of a specific sequence with antisense inhibition (38). It is also 
resistant to enzymatic degradation and remains in tissues for long periods of time (39, 40). 
Therefore, it is a promising molecule that can be designed to inhibit expression of genes 
conferring antimicrobial resistance. Previously, it was shown that PNA-mediated antisense 
translational inhibition of the TEM-1 β-lactamase re-sensitize drug-resistant Escherichia coli to 
β-lactam antibiotics (41). PNA was also designed to inhibit the expression of the CmeABC 
efflux pump (42). The CmeA1 PNA (anti-CmeA PNA) was able to reduce the production of 
CmeA as confirmed by western blots and was successful at increasing the susceptibility of 
Campylobacter to ciprofloxacin and erythromycin (16). We have also established that the 
CmeA1 PNA is able to reduce the emergence of ciprofloxacin resistant mutants under selection 
pressure in vitro (Chapter 3). Despite these advances, the in vivo efficacy of PNA in inhibiting 
CmeABC and sensitizing Campylobacter to antibiotics has not been examined. To close this 
knowledge gap, we conducted in vivo treatment studies using chicken as an animal model.  
 
Materials and Methods 
Bacterial Strains and Growth Conditions  
C. jejuni strains were cultured microaerobically in a gas chamber filled with 5% O2, 10% 
CO2 and 85% N2 on Mueller-Hinton (MH) agar or in Mueller-Hinton (MH) broth at 42 °C. All 
strains were preserved as 30% glycerol stock at -80°C. Two strains were used in this study, 
NCTC 11168 and CT6:16L (ciprofloxacin MIC of both strains = 0.063 µg/ml). CT6:16L is a C. 
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jejuni isolate derived from commercial turkeys (43).  Both strains were confirmed to be motile 
prior to inoculation into the chickens.  
Antimicrobial Susceptibility Tests 
Ciprofloxacin used to perform antimicrobial susceptibility tests in the laboratory was 
purchased from Sigma-Aldrich Co. LLC. The MIC was determined using the standard broth 
microdilution method in MH broth with an inoculum of 106 CFU/ml as previously described 
(44). Round bottomed 96 well culture plates were used, which were incubated for 24 hours under 
microaerophilic conditions at 42 °C. C. jejuni NCTC 11168 was used as a quality control for the 
test. 
PNA Preparation  
Based on the results from previous work.(42), the Peptide Nucleic Acid (PNA) CmeA1 
that binds to the translational start region of cmeA was synthesized and conjugated with a cell 
penetrating peptide (CPP) by PNA BIO INC (Newbury Park, CA). The CmeA1 sequence is as 
follows: KFFKFFKFFK-tgccttgaaaaa. The PNA was received as a lyophilized powder that was 
then reconstituted using autoclaved dd.H2O to a stock concentration of 2,000 µM or 4,000 µM, 
aliquoted into vials, and stored at -20°C for use. 
Antibiotic Treatment via Drinking Water  
Enrofloxacin (Sigma-Aldrich Co. LLC., USA) was administered to chickens via drinking 
water as described previously (21). The antibiotic was dissolved in DMSO to make a 10 mg/ml 
solution, 5 ml of which was added to 1L of tap water to make a drinking solution with 50 ppm of 
enrofloxacin. The drinking water for the non-treated group of chickens did not have antibiotic 
but had the same concentration of DMSO diluted in tap water (5 ml in 1L). Fresh drinking water 
solutions were prepared each day and given to the chickens during the treatment period. 
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Collection of Cloacal Swabs and Cecal Contents  
Cloacal swabs and cecal contents were collected during the chicken experiments to 
determine C. jejuni colonization levels and emergence of fluoroquinolone-resistant 
Campylobacter in the intestinal tract. Sterile cotton swabs were used to collect approximately 
100 mg feces from each chicken. The individual swabs were placed in sterile tubes with 1ml MH 
broth until they were processed. Cecal contents were collected from 1 or both ceca after 
euthanasia and necropsy of the chickens. Approximately 500 mg feces was collected from each 
bird and kept on ice until processed. 
Campylobacter CFU Enumeration  
The cloacal swabs were diluted in MH broth with 10-fold dilution series. For each 
dilution, 100 µl was plated onto a MH agar plate. To culture Campylobacter from feces, 
Campylobacter growth supplements and Campylobacter selective supplements (Oxoid) were 
added to the MH media to reduce the growth of background bacterial flora. The plates were 
incubated at 42 °C microaerobically for 48 hours for total CFU counts of Campylobacter. In 
parallel, the fecal dilutions were also plated onto Campylobacter selective MH agar plates with 
ciprofloxacin (4 µg/ml) to obtain fluoroquinolone-resistant Campylobacter CFU per gram of 
feces. The CFU/g of feces was calculated based on the colony counts and dilution factors. For 
the cecal contents, the amount of feces was first weighed, and then 10-fold dilution series were 
made in MH broth. Culturing methods and conditions as well as calculation of CFU/gram of 
feces were done in the same as cloacal swabs mentioned above. 
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Statistical Analysis  
An unpaired student’s t test was used to compare the average Campylobacter CFU/g of 
feces between different treatment groups in the chicken experiments. P values of < 0.05 were 
deemed to be statistically significant. Graphpad prism 8 software was used to generate the 
graphs. 
Design of Chicken Trial 1  
Day-old layer (white leghorn) chickens were obtained from a commercial hatchery. The 
chickens were randomly divided into 5 treatment groups, each group was housed in a dedicated 
wire floored brooder to avoid cross contamination between groups. Treatment groups are listed 
below in Table .  
Table 1. Treatment groups for Trial 1. 
Group Treatment No. of chicks 
1 Enrofloxacin (50ppm) 6 
2 Enrofloxacin (50ppm) + PNA (0.2 µmoles/day) 5 
3 Enrofloxacin (50ppm) + PNA (2 µmoles/day) 5 
4 PNA (2 µmoles/day) 5 
5 No Treatment 5 
 
Prior to inoculation, the birds were tested negative for Campylobacter by culturing 
cloacal swabs as detailed above. At 5 days of age, each chicken was inoculated with 200 µl of 
106 CFU/ml C. jejuni 11168 (Cipro MIC 0.063 µg/ml) via oral gavage. Five days post 
inoculation (DPI), cloacal swabs were collected to confirm Campylobacter colonization. Feed 
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and water were provided ad libitum. On DPI 7, treatment was initiated in drinking water. Groups 
1-4 received enrofloxacin or PNA or both (Table 1), while group 5 was given regular water with 
DMSO. Enrofloxacin was administered in drinking water, while PNA was given via oral gavage 
(once a day). The treatment lasted for 5 days, from DPI 7 to DPI 11. Cloacal swabs were 
collected periodically for culturing Campylobacter. On DPI 16, all chickens were euthanized and 
cecal contents were collected for quantitative enumeration of Campylobacter CFUs. 
Design of Chicken Trial 2  
Based on the results of trial 1, we modified the treatment and sampling schemes in trial 2. 
Day-old layer (white leghorn) chickens were obtained from a commercial hatchery. The chickens 
were divided into 4 treatment groups as listed in Table 2. Prior to inoculation, the birds were 
tested negative for Campylobacter by culturing cloacal swabs as detailed above. At 4 days of age 
each chicken was inoculated with 200 µl of 107 CFU/ml C. jejuni CT6:16L (Cipro MIC = 
0.063µg/ml) via oral gavage. On DPI 5, cloacal swabs were collected to confirm Campylobacter 
colonization. Feed and water were provided ad libitum.  
Table 2. Treatment groups for Trial 2. 
Group Treatment No. of chicks 
1 Enrofloxacin (50ppm) 14 
2 Enrofloxacin (50ppm) + PNA (2 µmoles/day) 12 
3 PNA (2 µmoles/day) 6 
4 No Treatment 8 
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On DPI 7, treatment was started. Based on the result of trial 1, the lower PNA dose (0.2 
µmoles per day) was not used because it was not effective. The treatments were conducted in the 
same manner as described for trial 1 and lasted for 5 days, from DPI 7 to DPI 11. Cloacal swabs 
were collected on DPI 8, 24 hours after the first PNA treatment. On DPI 9 (after 2 days of 
treatment), 4 chickens each from group 1 and 2 were euthanized and cecal contents were 
collected, while 3 chickens each from group 3 and 4 were terminated by euthanasia for collection 
of cecal contents. On DPI 11 (after 4 days of treatment), 4 chicken from each of groups 1 and 2 
were necropsied for collection of cecal contents. All the remaining chickens were euthanized on 
DPI 12 (1 day after the end of treatment) and their cecal contents were collected for culturing 
Campylobacter.  
Design of Chicken Trial 3  
A major change in trial 3 was to increase the dosing frequency of PNA to determine 
whether it provided better potentiating effect on enrofloxacin. The same dosage (2 µmoles) of 
PNA was given to each chicken twice a day instead of once a day, and the treatment was given 
for 4 days. Again, 1 day-old layer (white leghorn) chickens were obtained from a commercial 
hatchery and were divided into 4 treatment groups as listed in Table 3. As was the case with 
previous trials, cloacal swabs were collected to confirm the birds were free of Campylobacter 
prior to inoculation. Each bird was inoculated with 200 µl of 106 CFU/ml C. jejuni CT6:16L 
(Cipro MIC 0.063µg/ml) via oral gavage at 8 days of age. On DPI 5, cloacal swabs were 
collected to confirm Campylobacter colonization. Feed and water were provided ad libitum.  
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Table 3. Treatment groups for Trial 3. 
Group Treatment No. of chicks 
1 Enrofloxacin (50ppm) 10 
2 Enrofloxacin (50ppm) + PNA (2 µmoles twice a day) 10 
3 PNA (2 µmoles twice a day) 6 
4 No Treatment 4 
 
On DPI 7, treatment was initiated (see Table 3 for treatment scheme) and the treatment 
lasted for 4 days, from DPI 7 to DPI 10. Cloacal swabs were collected on DPI 7 before the start 
of treatment and on DPI 8 after 24hours of first treatment. On DPI 9 (after 2 days of treatment), 5 
chickens each from groups 1 and 2 were euthanized and cecal contents were collected for 
culturing Campylobacter. Also, 3 chickens from group 3 and 2 chickens from group 4 were 
euthanized for necropsy and cecal contents. On DPI 11(one day after the end of treatment), all 
remaining chickens were euthanized for collection of cecal contents.  
 
Results 
Determination of PNA Doses  
As seen in Figure 1, by DPI 5 the chickens were all colonized with Campylobacter.  Before 
initiation of the treatment with enrofloxacin, all the chickens had ciprofloxacin susceptible 
Campylobacter (Fig. 1B and 1D). The CFU counts dropped on DPI 8 (24 hours after initiation of 
treatment) in the groups receiving enrofloxacin treatment. In the group that only received 
enrofloxacin, the CFU counts rapidly rebounded due to emergence of resistant mutants as the 
treatment progressed, consistent with the results from previous treatment experiments in chickens 
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(21, 22, 45). The groups co-treated with the low-dose PNA did not appear to affect the 
development of ciprofloxacin-resistant mutants (Fig. 1 A and 1B); however, the group that was 
co-treated with the high dose of PNA consistently showed lower CFU counts (Figure 1C and 1D), 
indicating that PNA reduced the emergence of resistant Campylobacter when PNA was given 
together with enrofloxacin. Although there was a clear trend of reduction in CFU counts in the 
high dose PNA co-treated group, the differences were not statistically significant, probably due to 
variability between animals and the small number of animals in each group. Regardless, the results 
indicate that the low dose of PNA (0.2 µmoles/bird/day) is not sufficient to potentiate the effect of 
antibiotic treatment. There were no significant differences in colonization levels of the 2 control 
groups: PNA only and No Treatment (Figure 1E), indicating that PNA alone did not affect 
Campylobacter colonization in chickens. Additionally, no Ciprofloxacin resistant colonies were 
detected in the control groups during the entire course of experiment (Figure 1F). 
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Figure 1. CFU enumeration of C. jejuni 11168 from chicken cloacal swabs. (A) Comparison of 
total CFU counts in chickens from 2 treatment groups: Enro only and Enro + low dose PNA.  (B) 
Comparison of FQ-resistant CFU counts in chickens from 2 treatment groups: Enro only and Enro 
+ low dose PNA.  (C) Comparison of total CFU counts in chickens from 2 treatment groups: Enro 
only and Enro + high dose PNA.  (D) Comparison of FQ-resistant CFU counts in chickens from 2 
treatment groups Enro only and Enro + high dose PNA. (E) Comparison of total CFU counts in 
chickens from 2 control groups: High dose PNA only and No treatment.  (F) Comparison of FQ-
resistant CFU counts in chickens from 2 control groups: High dose PNA only and No treatment. 
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Effect of PNA on a Different C. jejuni Strain  
Similar to C. jejuni 11168, C. jejuni CT6:16L was able to colonize chickens by 5 days 
post inoculation (Fig. 2A). All the chickens were colonized by ciprofloxacin susceptible 
Campylobacter before the initiation of treatment (Figure 2C). CFU counts in cloacal swabs 
significantly decreased on DPI 8 (24 hours after initiation of treatment) in the groups receiving 
enrofloxacin treatment. However, ciprofloxacin-resistant Campylobacter emerged rapidly in the 
groups treated with enrofloxacin. Compared to the group treated with enrofloxacin only, the 
group that was co-treated with PNA displayed reduced CFU counts of ciprofloxacin-resistant 
Campylobacter, and the difference was statistically significant on DPI 11 (Figure 2B and 2D). 
Different from experiment 1 (Fig. 1), in which CFU counts were obtained from cloacal swabs, 
cecal contents derived from necropsy were used to enumerate the Campylobacter CFUs after 
initiation of the treatment. Use of cecal contents for CFU counts reduced variability between 
animals within a group. After the termination of treatment (DPI 12), there was no longer 
significant difference in the CFU counts between the 2 treatment groups (enrofloxacin alone and 
enrofloxacin plus PNA) (Fig. 2B and 2D). In the control groups (PNA only and no treatment), no 
ciprofloxacin-resistant Campylobacter was detected during the experiment (Figure 2C and 2D). 
Overall, the results indicate that co-treatment with PNA reduces but does not eliminate the 
emergence of fluoroquinolone resistant mutants during treatment with fluoroquinolone 
antibiotics.  
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Figure 2. CFU enumeration of C. jejuni CT6:16L from chicken cloacal swabs and cecal contents. 
(A) Total CFU counts in chicken cloacal swabs from DPI 0 to 8. (B) Total CFU counts in chicken 
cecal contents from DPI 9-12. (C) Fluoroquinolone-resistant CFU counts in chicken cloacal swabs 
from DPI 5-8. (D) Fluoroquinolone-resistant CFU counts in chicken cecal contents from DPI 9-
12. * and ** indicate statistically significant differences (p < 0.05 and p < 0.01, respectively). ns 
indicates not statistically significant. 
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Effect of PNA Dosing Frequencies  
Similar to the results from Trial 1 and Trial 2, the chickens were colonized by C. jejuni 
by DPI 5 as determined by culturing cloacal swabs (Figure 3A). Once treatment with 
enrofloxacin was initiated, the CFU counts dropped drastically, but resistant mutants emerged 
quickly in the treated birds (Fig, 3B, 3C, and 3D). The group co-treated with PNA had lower 
CFU counts than the group treated with enrofloxacin only, and the reduction in total CFU was 
statistically significant on DPI 9 (Fig. 3B). After the termination of treatment there was no longer 
difference in the CFU counts between the 2 treatment groups. Ciprofloxacin CFU counts on DPI 
9 revealed a trend of reduction in the PNA co-treated group, but the difference was not 
statistically significant (Fig. 3D), Together, the results suggest that increasing dosing frequency 
of PNA (twice per day) did not further enhance its potentiating effect on enrofloxacin. 
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Figure 3. CFU enumeration of C. jejuni CT6:16L in chicken cloacal swabs and cecal contents. (A) 
Total CFU counts in chicken cloacal swabs from DPI 0-8. (B) Total CFU counts from chicken 
cecal contents from DPI 9-11. (C) Cipro resistant CFU counts in chicken cloacal swabs from DPI 
0-8. (D) Cipro resistant CFU counts in chicken cecal contents from DPI 9-11. *indicates 
statistically significant difference (p < 0.05). 
 
Confirmation of Ciprofloxacin Resistance  
In addition to measuring ciprofloxacin resistant CFUs by use of differential plating, we 
also picked single colonies for confirmation of their susceptibility to ciprofloxacin. A single 
colony was randomly collected from the non-antibiotic plate of each sample at each sampling 
time and subsequently purified by subculture. All the collected isolates were identified using 
MALDI-TOF MS to confirm that they were C. jejuni.  All the isolates were first examined on 
MH agar plates containing ciprofloxacin (4 µg/ml). The colonies isolated from the control 
groups (PNA only and No treatment) of the three trials were always not able to grow on the 
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plates, indicating they were susceptible to ciprofloxacin.  In all 3 trials, all isolates collected from 
enrofloxacin treatment groups prior to the initiation of the treatment were susceptible to 
ciprofloxacin.  
The isolates picked on DPI 8, one day after the initiation of treatment, were still 
susceptible and this was likely that resistant mutants just started to emerge and remained low in 
number in the treated birds. On DPI 9 ( 2 days after initiation of the treatment), 6 out of the 8 
colonies picked from Trial 1 were resistant to ciprofloxacin, 5 out of the 6 colonies picked from 
Trial 2 were resistant to ciprofloxacin and in Trial 3 all 9 colonies that were picked were resistant 
to ciprofloxacin. This indicates that the majority of the colonies (75% for trial 1, 83% for trial 2, 
and 100% for trial 3) were resistant to ciprofloxacin by DPI 9 as determined by growth on plates 
containing 4 µg/ml of ciprofloxacin. From DPI 10 onwards, all the colonies picked from the 
chickens in the enrofloxacin-treated groups were resistant to ciprofloxacin. Furthermore, 1 
randomly selected isolate from the enrofloxacin-treated groups at each sampling day were 
subjected to antimicrobial susceptibility tests for MICs of ciprofloxacin. All susceptible isolates 
tested had an MIC of 0.063 µg/ml, while the resistant isolates had an MIC of 16 µg/ml. These 
results are consistent with the differential plating results and confirm the emergence of 
ciprofloxacin-resistant Campylobacter in enrofloxacin-treated birds. 
 
Discussion 
Result from this study exhibited that ciprofloxacin-resistant Campylobacter developed 
rapidly in chickens treated with enrofloxacin, and the PNA specifically targeting CmeABC 
efflux pump was able to reduce the emergence of fluoroquinolone resistant mutants in vivo. The 
potentiating effect of PNA was seen in the early stage of the treatment but was abolished as the 
treatment terminated. This effect was observed in all three trials (Figure 1, 2, and 3) and with 2 
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different strains of C. jejuni, These findings demonstrate the potential use of the anti-CmeABC 
PNA for in vivo treatment, but further studies are needed to optimize the dosages and delivery as 
the PNA did not eliminate the emergence of ciprofloxacin-resistant Campylobacter in this study. 
Trial 1 was performed using a laboratory strain C. jejuni NCTC 11168 as it was 
previously shown to be able to colonize chickens and ciprofloxacin-resistant mutants readily 
emerged in the chickens upon treatment with enrofloxacin (21, 22, 45). Since no previous in vivo 
studies have been conducted with an anti-cmeABC PNA delivered orally, we tested 2 different 
doses of PNA in the first trial. The doses were chosen based on the in vitro results and the 
expected complexity in the gastrointestinal contents. The results demonstrated that the lower 
dose (0.2 µmoles/bird/day) did not influence the emergence of ciprofloxacin-resistant mutants in 
enrofloxacin-treated birds (Figure 1A&B), while the high dose (2 µmoles/bird/day) appeared to 
reduce the emergence of fluoroquinolone resistant mutants. When analyzed statistically, the 
difference was not significant, probably due to the fact that cloacal swabs were used for CFU 
determination in trial 1, and it has been known that CFU counts tend to vary greatly even among 
birds inoculated with the same strain of C. jejuni. 
In trial 1, all of the birds in a group were housed within a single brooder, which means 
between-host transmission occurred within the same group. It is likely that even if ciprofloxacin-
resistant mutants developed in one bird, they would likely had transmitted to the other chickens 
in the same brooder. This can be seen in Figure 1D, on DPI9 and DPI10, only 2 out of the 5 
chickens in the enrofloxacin and PNA co-treated group developed ciprofloxacin resistant 
mutants, while in the group treated with enrofloxacin only, 3 out of 6 chickens developed 
ciprofloxacin resistant colonies on DPI9 and 5 out of 6 chickens on DPI10. On DPI 11, however, 
3 out of 5 chickens in the PNA co-treated group had resistant Campylobacter and on DPI 12 all 5 
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chickens were colonized with ciprofloxacin resistant Campylobacter. This indicates that the 
CmeA1 PNA was initially able to reduce the emergence of resistant mutants but was unable to 
completely inhibit the development of the mutants. 
Cecum is the primary site for Campylobacter colonization in chickens and CFU counts in 
cecal contents are better indicators for the level of colonization compared to the CFUs from 
cloacal swabs. Thus, in trial 2, birds were sacrificed after initiation of the treatment for collecting 
cecal contents, and total Campylobacter CFUs and ciprofloxacin-resistant CFUs were 
determined. Cloacal swabs were only collected initially to confirm colonization before treatment 
was started because of the need for sacrificing birds at different time points, the number of birds 
required for the treated groups were larger. Thus, in the 2nd trial, the birds in each of groups 1 
and 2 (Table 2) were divided into 4 different brooders. This was also expected to help limit 
between-bird transmission within the same group. The results of trial 2 showed the same trend as 
trial 1, but both total CFUs and ciprofloxacin-resistant CFUs were significantly reduced  on DPI 
11 in the enrofloxacin and PNA co-treated group compared to the group treated with 
ciprofloxacin only (Figure 2).  However, the colonization levels in the two groups became 
similar by the end of the treatment. These results further indicated that PNA was able to reduce 
but was unable to eliminate the emergence of fluoroquinolone resistant mutants in vivo. 
Based on the results of trials 1 and 2, we hypothesized that increasing dosing frequency 
of PNA might be able to enhance its potentiating effect on enrofloxacin. Thus, in trial 3, PNA 
was administered twice a day with a 12 hours interval. The results as seen in Figure 3, however, 
is much similar to the result of trial 2 (Figure 2), indicating that giving 2 doses a day did not 
further increase the efficacy of the PNA treatment. The result suggests that a higher dose of PNA 
77 
 
or improved delivery is needed to improve its efficacy in potentiating fluoroquinolone 
antibiotics. 
In the in vitro experiments using culture media, we were able to demonstrate that 
ciprofloxacin and CmeA1 PNA co-treatment completely eliminated the emergence of 
ciprofloxacin resistant mutants (chapter 3). This indicates the efficacy of the PNA and suggests 
that if present in sufficient concentration, the PNA should be able to completely inhibit the 
emergence of ciprofloxacin resistant mutants. However, the conditions in animal intestine are 
much more complex, and there are many variables and factors that may influence the efficacy of 
PNA in animal models. For example, Campylobacter only accounts for a tiny portion of the gut 
microbiota and the presence of other bacterial flora may significantly reduce the availability of 
PNA to Campylobacter. Additionally, the concentration of PNA in the gut cannot be controlled 
accurately due to gradient of concentrations existing in the gut and variable frequencies of 
defecation. Thus, the effective concentration of PNA in the ceca, where Campylobacter colonize, 
likely vary greatly from animal to animal. The stability of PNA in the intestinal tract is also 
unknown. In a previous study, rats were injected with a PNA intravenously, and  approximately 
90% of the total PNA given was recovered from the urine 24 hours after administration (40). 
Another study administered fluorescent labeled PNA intraperitoneally in mice once per week for 
3 weeks and they obtained good target inhibition (34). Unlike these studies, the CmeA1 PNA 
was administered orally and was exposed to the harsh environments in the gastrointestinal tract. 
All these factors discussed above may influence the efficacy of PNA and contribute to the 
variable effects in individual animals.  
Although PNA has been used against bacterial gene expression in vitro (41, 46, 47), its 
effectiveness in reducing bacterial load in animal models is rarely tested. In a study conducted in 
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BALB/c mice injected with E. coli to induce bacteremia and peritonitis, a PNA targeting an 
essential gene (acpP) was administered 30 mins before challenge intraperitoneally (48).  This 
resulted in a significant reduction of bacterial load in the blood. In the next set of experiments, 
they administered PNA intravenously 30 mins after challenge and again observed a significant 
reduction in bacterial load (48). Another study was conducted in the Galleria mellonella model 
of sepsis caused by Multidrug-resistant (MDR) Acinetobacter baumannii. Two doses (5 µM and 
20 µM) of PNA targeting an essential gene (carA) were evaluated by administering 30 mins post 
inoculation. Although the low dose of PNA did not demonstrate any effect the high dose was 
able to significantly reduce the mortality rate of the caterpillars (49). Different from these 
previously conducted studies, our animal experiments were performed by administering PNA 
into the intestinal tract of chickens. Campylobacter is an enteric organism and the chicken model 
is well established for evaluating Campylobacter colonization and emergence of fluoroquinolone 
resistance (50). To our knowledge, no previous animal studies have been reported, in which PNA 
is administered orally as a therapeutic or adjunct agent for antibiotics against bacteria. 
In contrast to EPIs for which the concentrations required for inhibition of efflux pumps 
are highly toxic to host cells, the CmeA1 PNA had no apparent adverse effects in vivo. The 
chickens inoculated with the PNA were as healthy as the ones not inoculated with PNA. There 
were no signs that the PNA caused any physiological effect on the chickens. In addition, PNA 
alone did not affect Campylobacter colonization or development of ciprofloxacin resistant 
mutants, suggesting that PNA itself doesn't serve as a selection force for Campylobacter. On the 
other hand, the CmeA1PNA showed a potentiating effect on enrofloxacin against two different 
strains of C. jejuni in the chicken model, indicating its potential as a adjunctive therapy for 
antibiotics.  However, more studies are necessary to optimize the treatment regime for PNA. For 
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example, higher PNA doses may be required to reach an effective concentration in the gut that 
completely eliminate the development of ciprofloxacin resistant mutants. Additionally, 
encapsulation of PNA may facilitate effective delivery to the intestinal tract via oral 
administration. Other routes of administration may also be tested and a time course measurement 
of PNA in the intestine and other tissues needs to be conducted to better understand the kinetics 
of PNA in animals. These remain to be determined in future studies. 
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CHAPTER 5.    GENERAL CONCLUSIONS 
 
The increasing prevalence of fluoroquinolone resistance in C. jejuni is a major concern 
for food safety and public health. Novel strategies are required to combat fluoroquinolone-
resistant Campylobacter. In this work, we performed both in vitro and in vivo studies to evaluate 
the efficacy of the CmeA1 PNA in potentiating fluoroquinolone antibiotic against C. jejuni. In 
the first set of experiments, fluoroquinolone-susceptible C. jejuni cultures were subjected to 
different treatment combinations. The culture treated only with ciprofloxacin developed resistant 
mutants that rapidly replaced the susceptible population. The ciprofloxacin and PNA co-treated 
culture, however, did not develop any resistant mutants. This was demonstrated in three 
independent experiments and was confirmed by spreading the cultures on antibiotic selective 
plates. Quantitative measurement of growth kinetics further revealed that the PNA not only 
prevented development of resistant mutants, but also resulted in faster killing of C. jejuni by 
ciprofloxacin. These findings exhibited the efficacy of PNA in preventing the emergence of 
fluoroquinolone resistant mutants in vitro. 
In the second set of experiments, the efficacy of PNA in potentiating fluoroquinolone 
antibiotics was evaluated using an in vivo model that involved Campylobacter infected chickens. 
Three chicken trials were conducted in total. In the first trial, 2 different PNA doses, 0.2 
µmoles/bird/day and 2 µmoles/bird/day, were evaluated. The result indicated that the low dose 
did not show a potentiating effect on enrofloxacin, while the high dose reduced the emergence of 
fluoroquinolone-resistant mutants in the birds treated with enrofloxacin. This finding was further 
supported by the second trial in which the chickens were infected by a different strain of C. 
jejuni. Again, the group of birds co-treated with ciprofloxacin and PNA showed an initially 
significantly reduction in the CFU number of fluoroquinolone-resistant mutants. To assess 
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whether PNA dosing frequencies affect its potentiating efficacy, the third chicken trial was 
conducted with the dose of 2 µmoles/bird given twice a day. The results from the third trial were 
similar to the second trial, indicating that 2 doses of PNA/ day did not further improve the 
efficacy. In all three experiments, chickens treated with ciprofloxacin alone consistently 
developed fluoroquinoclone-resistant C. jejuni, which eventually replaced the susceptible 
populations in the treated birds. On the contrary, the birds treated by PNA alone were colonized 
by fluoroquinolone-resistant Campylobacter throughout the study, indicating that PNA itself did 
not influence the development of resistant mutants. The results from these chicken studies 
demonstrate the potential of the CmeA1 PNA for in vivo use as an adjunct therapy. Together, the 
in vitro and in vivo data generated in this work reveal that the CmeA1 PNA is able to reduce the 
emergence of fluoroquinolone resistance in Campylobacter and potentiate the efficacy of 
antibiotic treatment, it can also be further developed for practical use in combating antibiotic 
resistant Campylobacter.  
 
Future Directions 
The CmeA1 PNA dosing and treatment regime needs to be optimized further to improve 
its efficacy in vivo. Unlike in vitro studies, the conditions in animal intestinal tract are much 
more complex, which requires additional experiments to evaluate the variables that affect PNA 
efficacy such as bioavailability. Furthermore, only a single antibiotic dose (50 ppm in drinking 
water) was used in the chicken trials describe above. Subsequent trials may be conducted using 
different antibiotic dosages to optimize the antibiotic-PNA combinations that allow for complete 
elimination of fluoroquiniolone-resistant mutants in treated animals. Additionally, different 
routes of administration like intra-peritoneal injections may be tested to assess which route 
provides the best bioavailability of the PNA in the gut. Furthermore, time dependent 
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measurement of PNA levels in the intestinal tract need to be conducted to evaluate the kinetics of 
PNA to determine how long it remains in the animal system as that would significantly impact 
the frequency of the doses. In conclusion, several experiments need to be conducted in the future 
to determine the most efficacious dose and frequency for PNA co treatment with antibiotics. 
